CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | imidazole fungicide |
|
Accession: | CHEBI:87068
|
browse the term
|
Definition: | Any imidazole antifungal agent that has been used as a fungicide. |
Synonyms: | related_synonym: | imidazole fungicides |
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport multiple interactions |
ISO |
ABCB1 protein results in increased transport of cyazofamid cyazofamid affects the reaction [ABCB1 protein results in increased uptake of Digoxin]; Verapamil inhibits the reaction [ABCB1 protein results in increased transport of cyazofamid] |
CTD |
PMID:32003934 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases uptake |
ISO |
ABCC2 protein results in increased uptake of cyazofamid |
CTD |
PMID:32003934 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases uptake |
ISO |
ABCG2 protein results in increased uptake of cyazofamid |
CTD |
PMID:32003934 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
decreases expression |
ISO |
cyazofamid results in decreased expression of CYP3A5 mRNA |
CTD |
PMID:34642769 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases activity |
ISO |
cyazofamid results in decreased activity of DIO1 protein |
CTD |
PMID:29228274 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Esrra |
estrogen related receptor, alpha |
increases activity |
ISO |
cyazofamid results in increased activity of ESRRA protein |
CTD |
PMID:20143881 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
multiple interactions |
ISO |
cyazofamid inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:32003934 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
multiple interactions |
ISO |
cyazofamid inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:32003934 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
cyazofamid inhibits the reaction [SLCO1B3 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:32003934 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
ISO |
enilconazole results in decreased expression of ABCB11 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of ABCC2 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
decreases expression multiple interactions increases expression |
ISO EXP |
enilconazole results in decreased expression of ABCC3 mRNA [enilconazole co-treated with clothianidin] results in increased expression of ABCC3 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ABCC3 mRNA enilconazole results in increased expression of ABCC3 mRNA |
CTD |
PMID:29451352 PMID:33426623 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcd3 |
ATP binding cassette subfamily D member 3 |
decreases expression |
ISO |
enilconazole results in decreased expression of ABCD3 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of ACOX1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Adk |
adenosine kinase |
increases expression |
ISO |
enilconazole results in increased expression of ADK mRNA |
CTD |
PMID:32201337 |
|
NCBI chr15:2,863,241...3,246,453
Ensembl chr15:2,863,244...3,246,510
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression multiple interactions increases expression |
ISO EXP |
enilconazole results in decreased expression of ALDH1A1 mRNA [enilconazole co-treated with clothianidin] results in increased expression of ALDH1A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ALDH1A1 mRNA enilconazole results in increased expression of ALDH1A1 mRNA [thiacloprid co-treated with enilconazole] results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:32201337 PMID:33426623 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases expression multiple interactions |
ISO |
enilconazole results in decreased expression of ALDH2 mRNA [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of ALDH2 mRNA; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of and results in decreased activity of ALDH2 protein |
CTD |
PMID:32201337 PMID:34830855 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Ano1 |
anoctamin 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of ANO1 mRNA |
CTD |
PMID:29106682 |
|
NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069
|
|
G |
Anxa10 |
annexin A10 |
increases expression |
ISO |
enilconazole results in increased expression of ANXA10 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases expression affects binding |
ISO |
Dihydrotestosterone inhibits the reaction [enilconazole results in increased activity of AR protein]; enilconazole inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; enilconazole inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; enilconazole inhibits the reaction [Metribolone results in increased activity of AR protein] enilconazole results in decreased expression of AR mRNA enilconazole binds to AR protein |
CTD |
PMID:15064155 PMID:18324785 PMID:21310686 PMID:30853599 PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arg1 |
arginase 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of ARG1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
increases expression |
ISO |
enilconazole results in increased expression of ATP8B1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Cat |
catalase |
increases expression |
ISO |
enilconazole results in increased expression of CAT mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
enilconazole results in increased expression of CCL5 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions decreases expression |
ISO |
[enilconazole co-treated with thiacloprid] results in increased expression of CES2 protein enilconazole results in decreased expression of CES2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cftr |
CF transmembrane conductance regulator |
affects binding decreases expression |
ISO |
enilconazole binds to CFTR protein enilconazole results in decreased expression of CFTR mRNA; enilconazole results in decreased expression of CFTR protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
ISO |
enilconazole results in increased expression of COMT protein |
CTD |
PMID:32201337 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
affects expression |
ISO |
enilconazole affects the expression of CYP11A1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression |
ISO |
enilconazole results in increased expression of CYP17A1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity affects secretion |
ISO |
enilconazole results in decreased activity of CYP19A1 protein enilconazole affects the secretion of CYP19A1 mRNA |
CTD |
PMID:10806373 PMID:15554355 PMID:26141389 PMID:30853599 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity increases expression multiple interactions |
ISO |
enilconazole results in increased activity of CYP1A1 protein enilconazole results in increased expression of CYP1A1 mRNA; enilconazole results in increased expression of CYP1A1 protein enilconazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:19070657 PMID:21762035 PMID:32194361 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects expression multiple interactions |
ISO |
enilconazole affects the expression of CYP1A2 mRNA [clothianidin co-treated with enilconazole] results in increased expression of CYP1A2 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP1A2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression multiple interactions |
ISO |
enilconazole results in increased expression of CYP1B1 mRNA [clothianidin co-treated with enilconazole] results in increased expression of CYP1B1 protein |
CTD |
PMID:32201337 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases expression |
ISO |
enilconazole results in increased expression of CYP27A1 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression multiple interactions |
EXP |
enilconazole results in increased expression of CYP2B2 mRNA [enilconazole co-treated with clothianidin] results in increased expression of CYP2B2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B2 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases expression affects expression |
ISO |
[enilconazole co-treated with thiacloprid] results in increased expression of CYP2B6 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP2B9 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B6 mRNA enilconazole results in increased expression of CYP2B10 enilconazole affects the expression of CYP2B6 mRNA |
CTD |
PMID:27853109 PMID:32201337 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases expression |
ISO |
enilconazole results in decreased expression of CYP2C19 mRNA; enilconazole results in decreased expression of CYP2C19 protein |
CTD |
PMID:32194361 PMID:32201337 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions decreases expression |
ISO |
[clothianidin co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA enilconazole results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects expression decreases activity multiple interactions increases expression |
ISO |
enilconazole affects the expression of CYP3A4 mRNA enilconazole results in decreased activity of CYP3A4 protein [Amiodarone co-treated with Benzoic Acid co-treated with cyproconazole co-treated with flusilazole co-treated with enilconazole co-treated with prochloraz co-treated with propiconazole co-treated with tebuconazole] results in increased expression of CYP3A4 protein; [clothianidin co-treated with enilconazole] results in increased expression of CYP3A4 mRNA; [clothianidin co-treated with enilconazole] results in increased expression of CYP3A4 protein; [enilconazole co-treated with methidathion] results in increased expression of CYP3A4 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP3A4 mRNA; [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A4 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A4 mRNA enilconazole results in increased expression of CYP3A4 protein |
CTD |
PMID:21762035 PMID:25028461 PMID:32201337 PMID:34273450 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions increases expression |
EXP |
[enilconazole co-treated with clothianidin] results in increased expression of CYP3A23-3A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A23-3A1 mRNA enilconazole results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression multiple interactions |
ISO |
enilconazole results in increased expression of CYP3A5 mRNA; enilconazole results in increased expression of CYP3A5 protein [clothianidin co-treated with enilconazole] results in increased expression of CYP3A5 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A5 protein |
CTD |
PMID:32201337 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases activity |
ISO |
enilconazole results in decreased activity of CYP51A1 protein |
CTD |
PMID:16989930 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410 Ensembl chr 6:30,036,865...30,055,410
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression multiple interactions |
ISO EXP |
enilconazole results in decreased expression of CYP7A1 mRNA [enilconazole co-treated with clothianidin] results in decreased expression of CYP7A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP7A1 mRNA enilconazole results in decreased expression of CYP7A1 mRNA; enilconazole results in decreased expression of CYP7A1 protein |
CTD |
PMID:29451352 PMID:32194361 PMID:32201337 PMID:32814239 PMID:33426623 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression |
ISO |
enilconazole results in increased expression of CYP8B1 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dnm1 |
dynamin 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of DNM1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 3:15,604,782...15,648,654
Ensembl chr 3:15,604,784...15,648,538
|
|
G |
Eln |
elastin |
decreases expression multiple interactions |
EXP |
enilconazole results in decreased expression of ELN mRNA [enilconazole co-treated with clothianidin] results in decreased expression of ELN mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of ELN mRNA |
CTD |
PMID:33426623 |
|
NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
enilconazole binds to and results in increased activity of ESR1 protein |
CTD |
PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
decreases expression multiple interactions |
ISO |
enilconazole results in decreased expression of ESR2 mRNA enilconazole binds to and results in increased activity of ESR2 protein |
CTD |
PMID:30853599 PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fabp6 |
fatty acid binding protein 6 |
decreases expression |
ISO |
enilconazole results in decreased expression of FABP6 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
enilconazole results in increased expression of FAS mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
decreases expression increases expression |
ISO |
enilconazole results in decreased expression of FGF15 mRNA enilconazole results in increased expression of FGF15 mRNA |
CTD |
PMID:29451352 PMID:32814239 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of G6PC1 mRNA |
CTD |
PMID:32194361 PMID:32201337 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
enilconazole results in increased expression of GPX1 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of GPX2 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression |
ISO |
enilconazole results in increased expression of GSR mRNA |
CTD |
PMID:29451352 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gss |
glutathione synthetase |
decreases expression |
ISO |
enilconazole results in decreased expression of GSS mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in increased expression of H2AX protein |
CTD |
PMID:34830855 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Haao |
3-hydroxyanthranilate 3,4-dioxygenase |
decreases expression |
ISO |
enilconazole results in decreased expression of HAAO mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 6:10,845,235...10,864,863
Ensembl chr 6:10,845,771...10,864,877
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
affects expression |
ISO |
enilconazole affects the expression of HMGCR mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
affects expression |
ISO |
enilconazole affects the expression of HMGCS1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hsd17b13 |
hydroxysteroid (17-beta) dehydrogenase 13 |
decreases expression |
ISO |
enilconazole results in decreased expression of HSD17B13 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr14:5,751,697...5,766,809
Ensembl chr14:5,752,132...5,768,166
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
affects expression |
ISO |
enilconazole affects the expression of HSD3B1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
enilconazole results in increased expression of IFNG mRNA |
CTD |
PMID:27393971 PMID:32814239 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il17a |
interleukin 17A |
multiple interactions increases expression |
ISO |
enilconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA] enilconazole results in increased expression of IL17A mRNA |
CTD |
PMID:22289359 PMID:32814239 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
enilconazole results in increased expression of IL1A mRNA |
CTD |
PMID:32814239 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
enilconazole results in increased expression of IL1B mRNA |
CTD |
PMID:27393971 PMID:32814239 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
enilconazole results in increased expression of IL6 mRNA |
CTD |
PMID:27393971 PMID:32201337 PMID:32814239 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
enilconazole results in increased expression of JUN mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Khk |
ketohexokinase |
decreases expression |
ISO |
enilconazole results in decreased expression of KHK mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 6:25,445,298...25,455,834
Ensembl chr 6:25,445,300...25,455,717
|
|
G |
Klf4 |
KLF transcription factor 4 |
affects expression decreases expression |
ISO |
enilconazole affects the expression of KLF4 mRNA enilconazole results in decreased expression of KLF4 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Ky |
kyphoscoliosis peptidase |
multiple interactions decreases expression |
EXP |
[enilconazole co-treated with clothianidin] results in decreased expression of KY mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of KY mRNA enilconazole results in decreased expression of KY mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 8:103,086,959...103,126,305
Ensembl chr 8:103,086,630...103,126,024
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
enilconazole results in increased expression of LCN2 |
CTD |
PMID:27393971 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Lhb |
luteinizing hormone subunit beta |
decreases expression |
EXP |
enilconazole results in decreased expression of LHB protein |
CTD |
PMID:36410587 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
ISO |
enilconazole results in increased expression of LPL mRNA |
CTD |
PMID:32201337 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Ly6d |
lymphocyte antigen 6 family member D |
decreases expression |
ISO |
enilconazole results in decreased expression of LY6D mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 7:106,643,225...106,644,733
Ensembl chr 7:106,643,232...106,644,733
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases expression |
ISO |
enilconazole results in increased expression of MAPK8 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Megf11 |
multiple EGF-like-domains 11 |
multiple interactions decreases expression |
EXP |
[enilconazole co-treated with clothianidin] results in decreased expression of MEGF11 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of MEGF11 mRNA enilconazole results in decreased expression of MEGF11 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 8:64,892,312...65,218,984
Ensembl chr 8:64,892,387...65,216,061
|
|
G |
Mep1b |
meprin A subunit beta |
affects expression decreases expression |
ISO |
enilconazole affects the expression of MEP1B mRNA enilconazole results in decreased expression of MEP1B mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr18:12,366,126...12,392,840
Ensembl chr18:12,365,289...12,392,840
|
|
G |
Mlxipl |
MLX interacting protein-like |
decreases expression |
ISO |
enilconazole results in decreased expression of MLXIPL mRNA |
CTD |
PMID:32201337 |
|
NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mme |
membrane metallo-endopeptidase |
multiple interactions increases expression |
EXP |
[enilconazole co-treated with clothianidin] results in increased expression of MME mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of MME mRNA enilconazole results in increased expression of MME mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
decreases expression |
ISO |
enilconazole results in decreased expression of MTTP mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Muc1 |
mucin 1, cell surface associated |
affects expression decreases expression |
ISO |
enilconazole affects the expression of MUC1 mRNA enilconazole results in decreased expression of MUC1 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733
|
|
G |
Muc17 |
mucin 17, cell surface associated |
decreases expression |
ISO |
enilconazole results in decreased expression of MUC17 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr12:19,527,251...19,536,924
Ensembl chr12:19,527,321...19,538,522
|
|
G |
Muc2 |
mucin 2, oligomeric mucus/gel-forming |
affects expression decreases expression |
ISO |
enilconazole affects the expression of MUC2 mRNA enilconazole results in decreased expression of MUC2 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions decreases expression |
ISO |
[clothianidin co-treated with enilconazole] results in decreased expression of NR0B2 mRNA enilconazole results in decreased expression of NR0B2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression increases expression |
ISO |
enilconazole results in decreased expression of NR1H4 mRNA enilconazole results in increased expression of NR1H4 mRNA |
CTD |
PMID:29451352 PMID:32814239 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases activity |
ISO |
[enilconazole co-treated with methidathion] results in increased activity of NR1I2 protein; enilconazole binds to and results in increased activity of NR1I2 protein; enilconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein] enilconazole results in increased activity of NR1I2 protein |
CTD |
PMID:16565514 PMID:17438109 PMID:21115097 PMID:25028461 PMID:29973476 PMID:33049310 More...
|
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions affects response to substance |
ISO |
enilconazole binds to and results in increased activity of NR1I3 protein; enilconazole inhibits the reaction [Androstane-3,17-diol binds to and results in decreased activity of NR1I3 protein] NR1I3 protein affects the susceptibility to enilconazole |
CTD |
PMID:18832183 PMID:27853109 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
decreases expression |
ISO |
enilconazole results in decreased expression of PDK4 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pnpla3 |
patatin-like phospholipase domain containing 3 |
decreases expression |
ISO |
enilconazole results in decreased expression of PNPLA3 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 7:115,293,538...115,314,077
Ensembl chr 7:115,293,538...115,314,077
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
enilconazole binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression |
ISO |
enilconazole results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:32201337 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[enilconazole binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2 |
CTD |
PMID:26359731 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases activity |
ISO |
enilconazole results in increased activity of RARA protein |
CTD |
PMID:20143881 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rarg |
retinoic acid receptor, gamma |
increases activity |
ISO |
enilconazole results in increased activity of RARG protein |
CTD |
PMID:20143881 |
|
NCBI chr 7:133,367,833...133,390,301
Ensembl chr 7:133,367,833...133,390,177
|
|
G |
Retnlb |
resistin like beta |
affects expression |
ISO |
enilconazole affects the expression of RETNLB mRNA |
CTD |
PMID:29106682 |
|
NCBI chr11:51,983,482...51,985,368
Ensembl chr11:51,983,483...51,985,368
|
|
G |
Rgcc |
regulator of cell cycle |
increases expression |
ISO |
enilconazole results in increased expression of RGCC mRNA |
CTD |
PMID:32201337 |
|
NCBI chr15:54,662,483...54,675,320
Ensembl chr15:54,662,483...54,681,141
|
|
G |
Rora |
RAR-related orphan receptor A |
multiple interactions |
ISO |
enilconazole binds to and results in decreased activity of RORA protein |
CTD |
PMID:22289359 |
|
NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
ISO |
enilconazole results in decreased expression of SCD mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
increases expression |
ISO |
enilconazole results in increased expression of SLC10A2 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC12A2 mRNA; enilconazole results in decreased expression of SLC12A2 protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC22A5 mRNA; enilconazole results in decreased expression of SLC22A5 protein |
CTD |
PMID:36150497 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc26a3 |
solute carrier family 26 member 3 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC26A3 mRNA; enilconazole results in decreased expression of SLC26A3 protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 6:48,023,892...48,064,829
Ensembl chr 6:48,023,892...48,064,772
|
|
G |
Slc26a6 |
solute carrier family 26 member 6 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC26A6 mRNA; enilconazole results in decreased expression of SLC26A6 protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 8:109,558,968...109,569,778
Ensembl chr 8:109,559,642...109,569,778
|
|
G |
Slc6a1 |
solute carrier family 6 member 1 |
multiple interactions |
EXP |
[enilconazole co-treated with clothianidin] results in decreased expression of SLC6A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of SLC6A1 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 4:147,448,961...147,482,295
Ensembl chr 4:147,466,965...147,482,293
|
|
G |
Slc9a3 |
solute carrier family 9 member A3 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC9A3 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 1:29,124,633...29,167,912
Ensembl chr 1:29,124,674...29,167,417
|
|
G |
Slco4a1 |
solute carrier organic anion transporter family, member 4a1 |
increases expression |
ISO |
enilconazole results in increased expression of SLCO4A1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 3:167,559,177...167,578,307
Ensembl chr 3:167,559,316...167,578,305
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression |
ISO |
enilconazole results in increased expression of SOD1 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of SOD2 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Star |
steroidogenic acute regulatory protein |
affects expression decreases expression |
ISO EXP |
enilconazole affects the expression of STAR mRNA enilconazole results in decreased expression of STAR mRNA |
CTD |
PMID:30853599 PMID:36410587 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Sult1b1 |
sulfotransferase family 1B member 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of SULT1B1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483
|
|
G |
Sult1c2a |
sulfotransferase family 1C member 2A |
increases expression |
ISO |
enilconazole results in increased expression of SULT1C2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734
|
|
G |
Tff3 |
trefoil factor 3 |
decreases expression |
ISO |
enilconazole results in decreased expression of TFF3 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
enilconazole binds to and results in decreased activity of THRA protein |
CTD |
PMID:33049310 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
enilconazole results in increased expression of TNF mRNA |
CTD |
PMID:27393971 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
decreases expression |
ISO |
enilconazole results in decreased expression of UGT2B7 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions increases expression |
ISO |
sulforaphane inhibits the reaction [fenamidone results in increased expression of ABCA1 mRNA] |
CTD |
PMID:27029645 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Acadl |
acyl-CoA dehydrogenase, long chain |
increases expression |
ISO |
fenamidone results in increased expression of ACADL mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
increases expression |
ISO |
fenamidone results in increased expression of ACADS mRNA |
CTD |
PMID:27029645 |
|
NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Acadvl |
acyl-CoA dehydrogenase, very long chain |
increases expression |
ISO |
fenamidone results in increased expression of ACADVL mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075
|
|
G |
Acsbg1 |
acyl-CoA synthetase bubblegum family member 1 |
increases expression |
ISO |
fenamidone results in increased expression of ACSBG1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:54,991,294...55,047,276
Ensembl chr 8:54,991,296...55,047,391
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions increases expression |
ISO |
sulforaphane inhibits the reaction [fenamidone results in increased expression of ACTA2 mRNA] |
CTD |
PMID:27029645 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actn1 |
actinin, alpha 1 |
increases expression |
ISO |
fenamidone results in increased expression of ACTN1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
increases expression |
ISO |
fenamidone results in increased expression of ADAMTS1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
increases expression |
ISO |
fenamidone results in increased expression of ADAMTS5 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G |
Adamtsl4 |
ADAMTS-like 4 |
increases expression |
ISO |
fenamidone results in increased expression of ADAMTSL4 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:183,235,634...183,247,091
Ensembl chr 2:183,235,646...183,246,848
|
|
G |
Adarb2 |
adenosine deaminase RNA specific B2 |
decreases expression |
ISO |
fenamidone results in decreased expression of ADARB2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr17:61,750,437...62,300,984
Ensembl chr17:61,756,067...62,300,831
|
|
G |
Adgre5 |
adhesion G protein-coupled receptor E5 |
increases expression |
ISO |
fenamidone results in increased expression of ADGRE5 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr19:24,397,972...24,418,648
Ensembl chr19:24,398,689...24,418,638
|
|
G |
Adgrg6 |
adhesion G protein-coupled receptor G6 |
increases expression |
ISO |
fenamidone results in increased expression of ADGRG6 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:8,812,889...8,954,239
Ensembl chr 1:8,812,904...8,954,123
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
increases expression |
ISO |
fenamidone results in increased expression of ADRB2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Ahnak |
AHNAK nucleoprotein |
increases expression |
ISO |
fenamidone results in increased expression of AHNAK mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926
|
|
G |
Ajuba |
ajuba LIM protein |
increases expression |
ISO |
fenamidone results in increased expression of AJUBA mRNA |
CTD |
PMID:27029645 |
|
NCBI chr15:28,019,775...28,031,537
Ensembl chr15:28,019,778...28,030,021
|
|
G |
Aldh4a1 |
aldehyde dehydrogenase 4 family, member A1 |
increases expression |
ISO |
fenamidone results in increased expression of ALDH4A1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:151,880,002...151,905,491
Ensembl chr 5:151,830,701...151,925,345
|
|
G |
Amotl1 |
angiomotin-like 1 |
increases expression |
ISO |
fenamidone results in increased expression of AMOTL1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:11,348,651...11,467,564
Ensembl chr 8:11,353,674...11,467,573
|
|
G |
Amotl2 |
angiomotin like 2 |
increases expression |
ISO |
fenamidone results in increased expression of AMOTL2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:103,303,368...103,319,161
Ensembl chr 8:103,302,992...103,318,910
|
|
G |
Angptl2 |
angiopoietin-like 2 |
increases expression |
ISO |
fenamidone results in increased expression of ANGPTL2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:16,517,185...16,547,024
Ensembl chr 3:16,517,420...16,548,178
|
|
G |
Anks1b |
ankyrin repeat and sterile alpha motif domain containing 1B |
decreases expression |
ISO |
fenamidone results in decreased expression of ANKS1B mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:24,313,339...25,479,307
Ensembl chr 7:24,312,843...25,477,693
|
|
G |
Anxa2 |
annexin A2 |
increases expression |
ISO |
fenamidone results in increased expression of ANXA2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Anxa3 |
annexin A3 |
increases expression |
ISO |
fenamidone results in increased expression of ANXA3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617
|
|
G |
Arhgap18 |
Rho GTPase activating protein 18 |
increases expression |
ISO |
fenamidone results in increased expression of ARHGAP18 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:18,403,531...18,637,306
Ensembl chr 1:18,403,537...18,637,256
|
|
G |
Arpc1b |
actin related protein 2/3 complex, subunit 1B |
increases expression |
ISO |
fenamidone results in increased expression of ARPC1B mRNA |
CTD |
PMID:27029645 |
|
NCBI chr12:9,482,176...9,495,772
Ensembl chr12:9,480,831...9,495,747
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
increases expression |
ISO |
fenamidone results in increased expression of ASAH1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
increases expression |
ISO |
fenamidone results in increased expression of ASS1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
fenamidone results in increased expression of ATF3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf5 |
activating transcription factor 5 |
increases expression |
ISO |
fenamidone results in increased expression of ATF5 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
|
|
G |
Atl1 |
atlastin GTPase 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of ATL1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:88,377,168...88,475,242
Ensembl chr 6:88,377,239...88,475,204
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
increases expression |
ISO |
fenamidone results in increased expression of ATP6V0D2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354
|
|
G |
Atp6v0e1 |
ATPase H+ transporting V0 subunit e1 |
increases expression |
ISO |
fenamidone results in increased expression of ATP6V0E mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression |
ISO |
fenamidone results in increased expression of AXL mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Bag3 |
BAG cochaperone 3 |
increases expression |
ISO |
fenamidone results in increased expression of BAG3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
|
|
G |
Bcl11b |
BCL11 transcription factor B |
decreases expression |
ISO |
fenamidone results in decreased expression of BCL11B mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:126,834,531...126,927,720
Ensembl chr 6:126,834,531...126,928,224
|
|
G |
Bean1 |
brain expressed, associated with NEDD4, 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of BEAN1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr19:739,551...786,395
Ensembl chr19:739,551...787,537
|
|
G |
Bhlhe41 |
basic helix-loop-helix family, member e41 |
increases expression |
ISO |
fenamidone results in increased expression of BHLHE41 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:178,834,264...178,838,618
Ensembl chr 4:178,834,271...178,838,468
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
decreases expression |
ISO |
fenamidone results in decreased expression of BNIP3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
fenamidone results in increased expression of BTG2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Cadps |
calcium dependent secretion activator |
decreases expression |
ISO |
fenamidone results in decreased expression of CADPS mRNA |
CTD |
PMID:27029645 |
|
NCBI chr15:12,289,803...12,742,786
Ensembl chr15:12,290,262...12,742,779
|
|
G |
Cald1 |
caldesmon 1 |
increases expression |
ISO |
fenamidone results in increased expression of CALD1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:63,265,781...63,446,938
Ensembl chr 4:63,265,942...63,446,932
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
decreases expression |
ISO |
fenamidone results in decreased expression of CAMK4 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Camta1 |
calmodulin binding transcription activator 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of CAMTA1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:161,510,283...162,356,902
Ensembl chr 5:161,510,283...162,356,723
|
|
G |
Car2 |
carbonic anhydrase 2 |
increases expression |
ISO |
fenamidone results in increased expression of CAR2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Caskin2 |
cask-interacting protein 2 |
increases expression |
ISO |
fenamidone results in increased expression of CASKIN2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:101,027,196...101,041,429
Ensembl chr10:101,027,260...101,041,414
|
|
G |
Cavin1 |
caveolae associated protein 1 |
increases expression |
ISO |
fenamidone results in increased expression of CAVIN1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:85,884,100...85,896,136
Ensembl chr10:85,889,036...85,896,120
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
fenamidone results in increased expression of CBR3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccdc141 |
coiled-coil domain containing 141 |
increases expression |
ISO |
fenamidone results in increased expression of CCDC141 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:61,948,614...62,109,968
Ensembl chr 3:61,948,646...62,110,079
|
|
G |
Cck |
cholecystokinin |
decreases expression |
ISO |
fenamidone results in decreased expression of CCK mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression |
ISO |
fenamidone results in increased expression of CCN1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccnd2 |
cyclin D2 |
increases expression |
ISO |
fenamidone results in increased expression of CCND2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnd3 |
cyclin D3 |
increases expression |
ISO |
fenamidone results in increased expression of CCND3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccng1 |
cyclin G1 |
increases expression |
ISO |
fenamidone results in increased expression of CCNG1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Ccsap |
centriole, cilia and spindle-associated protein |
decreases expression |
ISO |
fenamidone results in decreased expression of CCSAP mRNA |
CTD |
PMID:27029645 |
|
NCBI chr19:51,824,954...51,843,469
Ensembl chr19:51,826,994...51,842,753
|
|
G |
Cd151 |
CD151 molecule (Raph blood group) |
increases expression |
ISO |
fenamidone results in increased expression of CD151 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753
|
|
G |
Cd63 |
Cd63 molecule |
increases expression |
ISO |
fenamidone results in increased expression of CD63 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:1,325,108...1,340,447
Ensembl chr 7:1,325,103...1,399,178
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
ISO |
fenamidone results in increased expression of CD68 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cdc42ep1 |
CDC42 effector protein 1 |
increases expression |
ISO |
fenamidone results in increased expression of CDC42EP1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:110,395,287...110,403,203
Ensembl chr 7:110,395,332...110,403,200
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
fenamidone results in increased expression of CDKN1A mRNA |
CTD |
PMID:27029645 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
increases expression |
ISO |
fenamidone results in increased expression of CDKN1C mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
ISO |
fenamidone results in increased expression of CEBPB mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cemip |
cell migration inducing hyaluronidase 1 |
increases expression |
ISO |
fenamidone results in increased expression of CEMIP mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:137,906,921...138,062,430
Ensembl chr 1:137,908,920...138,062,415
|
|
G |
Cercam |
cerebral endothelial cell adhesion molecule |
increases expression |
ISO |
fenamidone results in increased expression of CERCAM mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:13,118,150...13,155,960
Ensembl chr 3:13,142,107...13,155,956
|
|
G |
Chac1 |
ChaC glutathione-specific gamma-glutamylcyclotransferase 1 |
increases expression |
ISO |
fenamidone results in increased expression of CHAC1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
|
|
G |
Chst3 |
carbohydrate sulfotransferase 3 |
increases expression |
ISO |
fenamidone results in increased expression of CHST3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr20:28,114,386...28,152,046
Ensembl chr20:28,114,404...28,121,807
|
|
G |
Ckb |
creatine kinase B |
increases expression |
ISO |
fenamidone results in increased expression of CKB mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Clec7a |
C-type lectin domain containing 7A |
increases expression |
ISO |
fenamidone results in increased expression of CLEC7A mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897
|
|
G |
Clic1 |
chloride intracellular channel 1 |
increases expression |
ISO |
fenamidone results in increased expression of CLIC1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712
|
|
G |
Cln5 |
CLN5, intracellular trafficking protein |
increases expression |
ISO |
fenamidone results in increased expression of CLN5 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr15:79,893,573...79,903,438
Ensembl chr15:79,893,548...79,903,438 Ensembl chr 2:79,893,548...79,903,438
|
|
G |
Clstn3 |
calsyntenin 3 |
decreases expression |
ISO |
fenamidone results in decreased expression of CLSTN3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cmtm3 |
CKLF-like MARVEL transmembrane domain containing 3 |
increases expression |
ISO |
fenamidone results in increased expression of CMTM3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr19:622,563...630,721
Ensembl chr19:604,458...629,790
|
|
G |
Cnn2 |
calponin 2 |
increases expression |
ISO |
fenamidone results in increased expression of CNN2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:9,712,505...9,719,678
Ensembl chr 7:9,712,516...9,719,656
|
|
G |
Cntnap4 |
contactin associated protein family member 4 |
decreases expression |
ISO |
fenamidone results in decreased expression of CNTNAP4 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr19:40,568,684...40,861,879
Ensembl chr19:40,568,684...40,854,656
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
increases expression |
ISO |
fenamidone results in increased expression of COL11A1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G |
Col12a1 |
collagen type XII alpha 1 chain |
increases expression |
ISO |
fenamidone results in increased expression of COL12A1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:80,547,592...80,665,665
Ensembl chr 8:80,547,593...80,665,686
|
|
G |
Col4a5 |
collagen type IV alpha 5 chain |
increases expression |
ISO |
fenamidone results in increased expression of COL4A5 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr X:105,118,762...105,322,699
Ensembl chr X:105,118,820...105,322,692
|
|
G |
Col4a6 |
collagen type IV alpha 6 chain |
increases expression |
ISO |
fenamidone results in increased expression of COL4A6 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr X:104,766,463...105,117,499
Ensembl chr X:104,766,957...105,117,500
|
|
G |
Col8a1 |
collagen type VIII alpha 1 chain |
increases expression |
ISO |
fenamidone results in increased expression of COL8A1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424
|
|
G |
Cpeb1 |
cytoplasmic polyadenylation element binding protein 1 |
increases expression |
ISO |
fenamidone results in increased expression of CPEB1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:135,300,048...135,407,688
Ensembl chr 1:135,300,461...135,409,760
|
|
G |
Cplx1 |
complexin 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of CPLX1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr14:1,184,677...1,216,392
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
ISO |
fenamidone results in increased expression of CPT1A mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Crtap |
cartilage associated protein |
increases expression |
ISO |
fenamidone results in increased expression of CRTAP mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:114,047,933...114,067,631
|
|
G |
Csf1 |
colony stimulating factor 1 |
increases expression |
ISO |
fenamidone results in increased expression of CSF1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csrp1 |
cysteine and glycine-rich protein 1 |
increases expression |
ISO |
fenamidone results in increased expression of CSRP1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr13:47,158,171...47,179,388
Ensembl chr13:47,167,789...47,179,384
|
|
G |
Cstb |
cystatin B |
increases expression |
ISO |
fenamidone results in increased expression of CSTB mRNA |
CTD |
PMID:27029645 |
|
NCBI chr20:10,245,462...10,247,505
Ensembl chr20:10,245,462...10,247,526
|
|
G |
Ctnna1 |
catenin alpha 1 |
increases expression |
ISO |
fenamidone results in increased expression of CTNNA1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr18:26,728,246...26,860,911
Ensembl chr18:26,728,485...26,860,910
|
|
G |
Ctsd |
cathepsin D |
increases expression |
ISO |
fenamidone results in increased expression of CTSD mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsl |
cathepsin L |
increases expression |
ISO |
fenamidone results in increased expression of CTSL mRNA |
CTD |
PMID:27029645 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Ctsz |
cathepsin Z |
increases expression |
ISO |
fenamidone results in increased expression of CTSZ mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:163,224,875...163,235,645
Ensembl chr 3:163,224,875...163,235,645
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
increases expression |
ISO |
fenamidone results in increased expression of CYBA mRNA |
CTD |
PMID:27029645 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Daam2 |
dishevelled associated activator of morphogenesis 2 |
increases expression |
ISO |
fenamidone results in increased expression of DAAM2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 9:11,428,913...11,546,982
Ensembl chr 9:11,428,724...11,545,497
|
|
G |
Dab2 |
DAB adaptor protein 2 |
increases expression |
ISO |
fenamidone results in increased expression of DAB2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476
|
|
G |
Dcxr |
dicarbonyl and L-xylulose reductase |
increases expression |
ISO |
fenamidone results in increased expression of DCXR mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:106,006,404...106,008,293
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
increases expression |
ISO |
fenamidone results in increased expression of DDR2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363
|
|
G |
Dennd2b |
DENN domain containing 2B |
increases expression |
ISO |
fenamidone results in increased expression of DENND2B mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:163,544,075...163,734,736
Ensembl chr 1:163,544,074...163,694,680
|
|
G |
Dffa |
DNA fragmentation factor subunit alpha |
decreases expression |
ISO |
fenamidone results in decreased expression of DFFA mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:159,540,715...159,553,639
Ensembl chr 5:159,540,715...159,553,633
|
|
G |
Dnm3 |
dynamin 3 |
decreases expression |
ISO |
fenamidone results in decreased expression of DNM3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr13:74,359,043...74,838,135
Ensembl chr13:74,359,213...74,838,108
|
|
G |
Dock1 |
dedicator of cyto-kinesis 1 |
increases expression |
ISO |
fenamidone results in increased expression of DOCK1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:189,467,143...189,983,777
Ensembl chr 1:189,467,143...189,983,768
|
|
G |
Dpp10 |
dipeptidyl peptidase like 10 |
decreases expression |
ISO |
fenamidone results in decreased expression of DPP10 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr13:34,584,420...36,269,292
Ensembl chr13:34,595,868...36,269,292
|
|
G |
Eci2 |
enoyl-CoA delta isomerase 2 |
increases expression |
ISO |
fenamidone results in increased expression of ECI2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr17:29,850,884...29,886,781
Ensembl chr17:29,870,391...29,886,781
|
|
G |
Eda2r |
ectodysplasin A2 receptor |
increases expression |
ISO |
fenamidone results in increased expression of EDA2R mRNA |
CTD |
PMID:27029645 |
|
NCBI chr X:62,224,763...62,269,333
Ensembl chr X:62,228,229...62,269,268
|
|
G |
Eef1a2 |
eukaryotic translation elongation factor 1 alpha 2 |
decreases expression |
ISO |
fenamidone results in decreased expression of EEF1A2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:168,265,893...168,275,071
Ensembl chr 3:168,195,357...168,275,071
|
|
G |
Efemp1 |
EGF containing fibulin extracellular matrix protein 1 |
increases expression |
ISO |
fenamidone results in increased expression of EFEMP1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr14:102,610,813...102,690,027
Ensembl chr14:102,610,908...102,690,018
|
|
G |
Egfr |
epidermal growth factor receptor |
increases expression |
ISO |
fenamidone results in increased expression of EGFR mRNA |
CTD |
PMID:27029645 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Ehd2 |
EH-domain containing 2 |
increases expression |
ISO |
fenamidone results in increased expression of EHD2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:76,639,568...76,658,747
Ensembl chr 1:76,637,482...76,658,783
|
|
G |
Ehd4 |
EH-domain containing 4 |
increases expression |
ISO |
fenamidone results in increased expression of EHD4 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:107,058,191...107,121,985
Ensembl chr 3:107,058,958...107,122,002
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
increases expression |
ISO |
fenamidone results in increased expression of EIF4EBP1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Elavl2 |
ELAV like RNA binding protein 2 |
decreases expression |
ISO |
fenamidone results in decreased expression of ELAVL2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:105,960,872...106,086,463
Ensembl chr 5:105,960,875...106,109,097
|
|
G |
Elk3 |
ETS transcription factor ELK3 |
increases expression |
ISO |
fenamidone results in increased expression of ELK3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:27,768,582...27,831,088
Ensembl chr 7:27,768,599...27,804,084
|
|
G |
Eln |
elastin |
increases expression |
ISO |
fenamidone results in increased expression of ELN mRNA |
CTD |
PMID:27029645 |
|
NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928
|
|
G |
Elovl1 |
ELOVL fatty acid elongase 1 |
increases expression |
ISO |
fenamidone results in increased expression of ELOVL1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:131,961,478...131,965,961
Ensembl chr 5:131,961,322...131,965,958
|
|
G |
Enox1 |
ecto-NOX disulfide-thiol exchanger 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of ENOX1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr15:52,517,833...53,079,752
Ensembl chr15:52,515,178...53,079,749
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
increases expression |
ISO |
fenamidone results in increased expression of EPAS1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Epha2 |
Eph receptor A2 |
increases expression |
ISO |
fenamidone results in increased expression of EPHA2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
ISO |
fenamidone results in increased expression of EPHX1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Etfb |
electron transfer flavoprotein subunit beta |
increases expression |
ISO |
fenamidone results in increased expression of ETFB mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:93,851,908...93,866,072
Ensembl chr 1:93,851,858...93,866,068
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
increases expression |
ISO |
fenamidone results in increased expression of ETS1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
|
|
G |
Evc |
EvC ciliary complex subunit 1 |
increases expression |
ISO |
fenamidone results in increased expression of EVC mRNA |
CTD |
PMID:27029645 |
|
NCBI chr14:73,456,181...73,498,955
Ensembl chr14:73,456,222...73,498,099
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
increases expression |
ISO |
fenamidone results in increased expression of F2R mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
fenamidone results in increased expression of F3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Faim2 |
Fas apoptotic inhibitory molecule 2 |
decreases expression |
ISO |
fenamidone results in decreased expression of FAIM2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:130,632,368...130,659,353
Ensembl chr 7:130,633,348...130,659,168
|
|
G |
Fat1 |
FAT atypical cadherin 1 |
increases expression |
ISO |
fenamidone results in increased expression of FAT1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr16:47,177,253...47,296,261
Ensembl chr16:47,177,248...47,296,107
|
|
G |
Fbn1 |
fibrillin 1 |
increases expression |
ISO |
fenamidone results in increased expression of FBN1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889
|
|
G |
Fbxo9 |
f-box protein 9 |
decreases expression |
ISO |
fenamidone results in decreased expression of FBXO9 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:78,958,482...78,984,015
Ensembl chr 8:78,958,483...78,983,949
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
increases expression |
ISO |
fenamidone results in increased expression of FGFR1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
increases expression |
ISO |
fenamidone results in increased expression of FGFR3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fkbp10 |
FKBP prolyl isomerase 10 |
increases expression |
ISO |
fenamidone results in increased expression of FKBP10 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:85,345,434...85,357,998
Ensembl chr10:85,346,126...85,427,330
|
|
G |
Fkbp9 |
FKBP prolyl isomerase 9 |
increases expression |
ISO |
fenamidone results in increased expression of FKBP9 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:86,106,256...86,156,723
Ensembl chr 4:86,106,282...86,156,721
|
|
G |
Flna |
filamin A |
increases expression |
ISO |
fenamidone results in increased expression of FLNA mRNA |
CTD |
PMID:27029645 |
|
NCBI chr X:152,007,758...152,034,266
Ensembl chr X:152,007,758...152,031,052
|
|
G |
Flnb |
filamin B |
increases expression |
ISO |
fenamidone results in increased expression of FLNB mRNA |
CTD |
PMID:27029645 |
|
NCBI chr15:16,961,999...17,095,059
Ensembl chr15:16,962,003...17,095,006
|
|
G |
Flnc |
filamin C |
increases expression |
ISO |
fenamidone results in increased expression of FLNC mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844
|
|
G |
Fn1 |
fibronectin 1 |
increases expression |
ISO |
fenamidone results in increased expression of FN1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Frmd8 |
FERM domain containing 8 |
increases expression |
ISO |
fenamidone results in increased expression of FRMD8 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:203,143,216...203,163,868
Ensembl chr 1:203,143,218...203,163,870
|
|
G |
Fzd7 |
frizzled class receptor 7 |
increases expression |
ISO |
fenamidone results in increased expression of FZD7 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 9:60,931,433...60,934,252
Ensembl chr 9:60,930,875...60,935,781
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of GAD1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
decreases expression |
ISO |
fenamidone results in decreased expression of GAD2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
fenamidone results in increased expression of GADD45A mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Galnt9 |
polypeptide N-acetylgalactosaminyltransferase 9 |
decreases expression |
ISO |
fenamidone results in decreased expression of GALNT9 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr12:46,050,395...46,128,626
Ensembl chr12:46,050,413...46,128,578
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
fenamidone results in increased expression of GDF15 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gjd2 |
gap junction protein, delta 2 |
decreases expression |
ISO |
fenamidone results in decreased expression of GJD2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:100,771,450...100,776,134
Ensembl chr 3:100,772,062...100,775,061
|
|
G |
Glmp |
glycosylated lysosomal membrane protein |
increases expression |
ISO |
fenamidone results in increased expression of GLMP mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:173,794,273...173,797,863
Ensembl chr 2:173,794,255...173,799,960
|
|
G |
Glra2 |
glycine receptor, alpha 2 |
decreases expression |
ISO |
fenamidone results in decreased expression of GLRA2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr X:29,020,377...29,241,666
Ensembl chr X:29,020,557...29,241,666
|
|
G |
Gls |
glutaminase |
decreases expression |
ISO |
fenamidone results in decreased expression of GLS mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gltp |
glycolipid transfer protein |
increases expression |
ISO |
fenamidone results in increased expression of GLTP mRNA |
CTD |
PMID:27029645 |
|
NCBI chr12:41,907,168...41,927,321
Ensembl chr12:41,907,144...41,927,319
|
|
G |
Gng12 |
G protein subunit gamma 12 |
increases expression |
ISO |
fenamidone results in increased expression of GNG12 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:96,011,118...96,134,767
Ensembl chr 4:96,010,952...96,134,712
|
|
G |
Gpnmb |
glycoprotein nmb |
increases expression |
ISO |
fenamidone results in increased expression of GPNMB mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
|
|
G |
Gpr22 |
G protein-coupled receptor 22 |
decreases expression |
ISO |
fenamidone results in decreased expression of GPR22 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:48,309,619...48,317,864
Ensembl chr 6:48,310,505...48,317,486
|
|
G |
Gpr88 |
G-protein coupled receptor 88 |
decreases expression |
ISO |
fenamidone results in decreased expression of GPR88 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:204,191,443...204,199,576
Ensembl chr 2:204,191,427...204,199,733
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
fenamidone results in increased expression of GPX1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Grik3 |
glutamate ionotropic receptor kainate type subunit 3 |
decreases expression |
ISO |
fenamidone results in decreased expression of GRIK3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:137,767,865...137,989,617
Ensembl chr 5:137,767,865...137,984,307
|
|
G |
Grn |
granulin precursor |
increases expression |
ISO |
fenamidone results in increased expression of GRN mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:87,387,672...87,393,777
Ensembl chr10:87,387,638...87,393,775
|
|
G |
Gss |
glutathione synthetase |
increases expression |
ISO |
fenamidone results in increased expression of GSS mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions increases expression |
ISO |
sulforaphane inhibits the reaction [fenamidone results in increased expression of GSTM1 mRNA] |
CTD |
PMID:27029645 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gtse1 |
G-2 and S-phase expressed 1 |
increases expression |
ISO |
fenamidone results in increased expression of GTSE1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:116,949,997...116,966,826
Ensembl chr 7:116,950,053...116,966,806
|
|
G |
Gxylt2 |
glucoside xylosyltransferase 2 |
increases expression |
ISO |
fenamidone results in increased expression of GXYLT2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:133,347,230...133,449,708
Ensembl chr 4:133,347,499...133,449,454
|
|
G |
Hacd4 |
3-hydroxyacyl-CoA dehydratase 4 |
increases expression |
ISO |
fenamidone results in increased expression of HACD4 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:102,887,597...102,915,376
Ensembl chr 5:102,887,588...102,915,338
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
increases expression |
ISO |
fenamidone results in increased expression of HADH mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Hapln1 |
hyaluronan and proteoglycan link protein 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of HAPLN1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:20,631,640...20,693,777
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
increases expression |
ISO |
fenamidone results in increased expression of HBEGF mRNA |
CTD |
PMID:27029645 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
sulforaphane inhibits the reaction [fenamidone results in increased expression of HMOX1 mRNA] |
CTD |
PMID:27029645 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hs3st2 |
heparan sulfate-glucosamine 3-sulfotransferase 2 |
decreases expression |
ISO |
fenamidone results in decreased expression of HS3ST2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:175,956,161...176,077,400
Ensembl chr 1:175,956,157...176,077,399
|
|
G |
Hspg2 |
heparan sulfate proteoglycan 2 |
increases expression |
ISO |
fenamidone results in increased expression of HSPG2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:149,677,437...149,778,594
Ensembl chr 5:149,677,476...149,778,594
|
|
G |
Hyal1 |
hyaluronidase 1 |
increases expression |
ISO |
fenamidone results in increased expression of HYAL1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:108,250,668...108,254,519
Ensembl chr 8:108,250,667...108,260,210
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
fenamidone results in increased expression of ICAM1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ier3 |
immediate early response 3 |
increases expression |
ISO |
fenamidone results in increased expression of IER3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583
|
|
G |
Ifi30 |
IFI30, lysosomal thiol reductase |
increases expression |
ISO |
fenamidone results in increased expression of IFI30 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr16:18,675,590...18,679,655
Ensembl chr16:18,675,613...18,681,175
|
|
G |
Ifitm2 |
interferon induced transmembrane protein 2 |
increases expression |
ISO |
fenamidone results in increased expression of IFITM2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:196,051,539...196,052,719
Ensembl chr 1:196,051,537...196,052,741
|
|
G |
Igdcc4 |
immunoglobulin superfamily, DCC subclass, member 4 |
increases expression |
ISO |
fenamidone results in increased expression of IGDCC4 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:65,621,893...65,657,651
Ensembl chr 8:65,621,897...65,657,648
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
increases expression |
ISO |
fenamidone results in increased expression of IGFBP3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Igfbpl1 |
insulin-like growth factor binding protein-like 1 |
increases expression |
ISO |
fenamidone results in increased expression of IGFBPL1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:60,076,428...60,091,833
Ensembl chr 5:60,076,429...60,091,833
|
|
G |
Il1rap |
interleukin 1 receptor accessory protein |
increases expression |
ISO |
fenamidone results in increased expression of IL1RAP mRNA |
CTD |
PMID:27029645 |
|
NCBI chr11:74,062,999...74,199,530
Ensembl chr11:74,070,304...74,199,530
|
|
G |
Inf2 |
inverted formin 2 |
increases expression |
ISO |
fenamidone results in increased expression of INF2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:131,649,162...131,675,944
Ensembl chr 6:131,649,211...131,675,941
|
|
G |
Ipcef1 |
interaction protein for cytohesin exchange factors 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of IPCEF1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:43,237,903...43,451,735
Ensembl chr 1:43,269,202...43,427,969
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
increases expression |
ISO |
fenamidone results in increased expression of IRAK1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521
|
|
G |
Itga3 |
integrin subunit alpha 3 |
increases expression |
ISO |
fenamidone results in increased expression of ITGA3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:79,990,160...80,022,206
Ensembl chr10:79,990,161...80,022,118
|
|
G |
Itga5 |
integrin subunit alpha 5 |
increases expression |
ISO |
fenamidone results in increased expression of ITGA5 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:134,478,963...134,502,837
Ensembl chr 7:134,478,968...134,502,837
|
|
G |
Itga6 |
integrin subunit alpha 6 |
increases expression |
ISO |
fenamidone results in increased expression of ITGA6 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428
|
|
G |
Itga7 |
integrin subunit alpha 7 |
increases expression |
ISO |
fenamidone results in increased expression of ITGA7 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:1,360,125...1,388,886
Ensembl chr 7:1,359,940...1,388,450
|
|
G |
Itgav |
integrin subunit alpha V |
increases expression |
ISO |
fenamidone results in increased expression of ITGAV mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639
|
|
G |
Itgb1 |
integrin subunit beta 1 |
increases expression |
ISO |
fenamidone results in increased expression of ITGB1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itprid2 |
ITPR interacting domain containing 2 |
increases expression |
ISO |
fenamidone results in increased expression of ITPRID2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:64,536,707...64,573,978
Ensembl chr 3:64,536,707...64,573,978
|
|
G |
Kank4 |
KN motif and ankyrin repeat domains 4 |
increases expression |
ISO |
fenamidone results in increased expression of KANK4 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:113,402,468...113,465,555
|
|
G |
Kcna1 |
potassium voltage-gated channel subfamily A member 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of KCNA1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:159,464,223...159,472,905
Ensembl chr 4:159,464,188...159,472,682
|
|
G |
Kcnc2 |
potassium voltage-gated channel subfamily C member 2 |
decreases expression |
ISO |
fenamidone results in decreased expression of KCNC2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:47,700,035...47,883,979
Ensembl chr 7:47,700,288...47,883,968
|
|
G |
Kcnh3 |
potassium voltage-gated channel subfamily H member 3 |
decreases expression multiple interactions |
ISO |
fenamidone results in decreased expression of KCNH3 mRNA sulforaphane inhibits the reaction [fenamidone results in decreased expression of KCNH3 mRNA] |
CTD |
PMID:27029645 |
|
NCBI chr 7:130,365,593...130,383,859
Ensembl chr 7:130,366,011...130,383,855
|
|
G |
Kcnv1 |
potassium voltage-gated channel modifier subfamily V member 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of KCNV1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:76,260,695...76,269,170
Ensembl chr 7:76,260,695...76,269,170
|
|
G |
Kif1c |
kinesin family member 1C |
increases expression |
ISO |
fenamidone results in increased expression of KIF1C mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:55,414,412...55,444,587
Ensembl chr10:55,415,900...55,443,545
|
|
G |
Kif5a |
kinesin family member 5A |
decreases expression |
ISO |
fenamidone results in decreased expression of KIF5A mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:63,051,894...63,089,024
Ensembl chr 7:63,049,424...63,092,858
|
|
G |
Kirrel1 |
kirre like nephrin family adhesion molecule 1 |
increases expression |
ISO |
fenamidone results in increased expression of KIRREL1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:172,521,644...172,615,057
Ensembl chr 2:172,525,245...172,615,299
|
|
G |
Klf3 |
KLF transcription factor 3 |
increases expression |
ISO |
fenamidone results in increased expression of KLF3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr14:43,474,767...43,505,801
Ensembl chr14:43,474,767...43,497,209
|
|
G |
Klf4 |
KLF transcription factor 4 |
increases expression |
ISO |
fenamidone results in increased expression of KLF4 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Lama5 |
laminin subunit alpha 5 |
increases expression |
ISO |
fenamidone results in increased expression of LAMA5 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:167,270,296...167,318,370
Ensembl chr 3:167,270,296...167,318,451
|
|
G |
Lamb1 |
laminin subunit beta 1 |
increases expression |
ISO |
fenamidone results in increased expression of LAMB1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585
|
|
G |
Lamb2 |
laminin subunit beta 2 |
increases expression |
ISO |
fenamidone results in increased expression of LAMB2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:109,178,367...109,190,552
Ensembl chr 8:109,178,409...109,190,549
|
|
G |
Lamc1 |
laminin subunit gamma 1 |
increases expression |
ISO |
fenamidone results in increased expression of LAMC1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr13:65,374,372...65,501,492
Ensembl chr13:65,374,372...65,501,492
|
|
G |
Lats2 |
large tumor suppressor kinase 2 |
increases expression |
ISO |
fenamidone results in increased expression of LATS2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr15:31,825,068...31,877,193
Ensembl chr15:31,825,092...31,877,220
|
|
G |
Lgals1 |
galectin 1 |
increases expression |
ISO |
fenamidone results in increased expression of LGALS1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345
|
|
G |
Lgals3 |
galectin 3 |
increases expression |
ISO |
fenamidone results in increased expression of LGALS3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
|
|
G |
Lgi1 |
leucine-rich, glioma inactivated 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of LGI1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:236,043,269...236,084,617
Ensembl chr 1:236,042,954...236,084,616
|
|
G |
Lhfpl6 |
LHFPL tetraspan subfamily member 6 |
increases expression |
ISO |
fenamidone results in increased expression of LHFPL6 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:137,126,485...137,324,442
Ensembl chr 2:137,126,509...137,324,443
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression |
ISO |
fenamidone results in increased expression of LIF mRNA |
CTD |
PMID:27029645 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Lima1 |
LIM domain and actin binding 1 |
multiple interactions increases expression |
ISO |
sulforaphane inhibits the reaction [fenamidone results in increased expression of LIMA1 mRNA] |
CTD |
PMID:27029645 |
|
NCBI chr 7:130,901,717...131,001,512
Ensembl chr 7:130,901,717...131,001,473
|
|
G |
Lipa |
lipase A, lysosomal acid type |
increases expression |
ISO |
fenamidone results in increased expression of LIPA mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:232,024,351...232,057,735
Ensembl chr 1:232,024,356...232,057,633
|
|
G |
Litaf |
lipopolysaccharide-induced TNF factor |
increases expression |
ISO |
fenamidone results in increased expression of LITAF mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763
|
|
G |
Lmod1 |
leiomodin 1 |
increases expression |
ISO |
fenamidone results in increased expression of LMOD1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr13:46,754,048...46,796,186
Ensembl chr13:46,754,033...46,794,900
|
|
G |
Lpp |
LIM domain containing preferred translocation partner in lipoma |
increases expression |
ISO |
fenamidone results in increased expression of LPP mRNA |
CTD |
PMID:27029645 |
|
NCBI chr11:75,787,326...76,426,646
Ensembl chr11:75,797,078...76,422,597
|
|
G |
Lrp2 |
LDL receptor related protein 2 |
increases expression |
ISO |
fenamidone results in increased expression of LRP2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:54,189,305...54,346,769
Ensembl chr 3:54,189,308...54,346,708
|
|
G |
Lrp5 |
LDL receptor related protein 5 |
increases expression |
ISO |
fenamidone results in increased expression of LRP5 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:200,814,247...200,917,581
Ensembl chr 1:200,814,250...200,917,581
|
|
G |
Lrrk1 |
leucine-rich repeat kinase 1 |
increases expression |
ISO |
fenamidone results in increased expression of LRRK1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:119,844,360...119,972,885
Ensembl chr 1:119,845,146...119,979,734
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
increases expression |
ISO |
fenamidone results in increased expression of LRRK2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:122,826,696...122,987,711
Ensembl chr 7:122,826,696...122,987,703
|
|
G |
Lsm11 |
LSM11, U7 small nuclear RNA associated |
decreases expression |
ISO |
fenamidone results in decreased expression of LSM11 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:30,367,841...30,385,956
Ensembl chr10:30,370,727...30,385,944
|
|
G |
Lzts1 |
leucine zipper tumor suppressor 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of LZTS1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr16:20,542,756...20,598,204
Ensembl chr16:20,542,809...20,598,203
|
|
G |
Maff |
MAF bZIP transcription factor F |
increases expression |
ISO |
fenamidone results in increased expression of MAFF mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851
|
|
G |
Man2b1 |
mannosidase, alpha, class 2B, member 1 |
increases expression |
ISO |
fenamidone results in increased expression of MAN2B1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr19:23,055,092...23,074,398
Ensembl chr19:23,055,097...23,074,389
|
|
G |
Man2b2 |
mannosidase, alpha, class 2B, member 2 |
increases expression |
ISO |
fenamidone results in increased expression of MAN2B2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr14:73,969,079...73,994,089
Ensembl chr14:73,969,003...74,004,281
|
|
G |
Map3k20 |
mitogen-activated protein kinase kinase kinase 20 |
increases expression |
ISO |
fenamidone results in increased expression of MAP3K20 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:57,130,539...57,289,943
Ensembl chr 3:57,130,551...57,289,626
|
|
G |
Mapkapk3 |
MAPK activated protein kinase 3 |
increases expression |
ISO |
fenamidone results in increased expression of MAPKAPK3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
increases expression |
ISO |
fenamidone results in increased expression of MCM2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847
|
|
G |
Mdk |
midkine |
increases expression |
ISO |
fenamidone results in increased expression of MDK mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130
|
|
G |
Msn |
moesin |
increases expression |
ISO |
fenamidone results in increased expression of MSN mRNA |
CTD |
PMID:27029645 |
|
NCBI chr X:60,996,043...61,064,011
Ensembl chr X:60,995,951...61,065,628
|
|
G |
Msrb3 |
methionine sulfoxide reductase B3 |
increases expression |
ISO |
fenamidone results in increased expression of MSRB3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:56,260,985...56,426,004
Ensembl chr 7:56,303,308...56,425,496
|
|
G |
Mthfd1 |
methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1 |
increases expression |
ISO |
fenamidone results in increased expression of MTHFD1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:94,977,862...95,045,375
Ensembl chr 6:94,977,862...95,045,372
|
|
G |
Mybl1 |
MYB proto-oncogene like 1 |
increases expression |
ISO |
fenamidone results in increased expression of MYBL1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:9,582,905...9,618,179
Ensembl chr 5:9,582,934...9,618,183
|
|
G |
Myh9 |
myosin, heavy chain 9 |
increases expression |
ISO |
fenamidone results in increased expression of MYH9 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:109,343,718...109,424,457
Ensembl chr 7:109,343,706...109,424,457
|
|
G |
Myl12a |
myosin light chain 12A |
increases expression |
ISO |
fenamidone results in increased expression of MYL12A mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 9:110,891,970...110,899,655
Ensembl chr 9:110,873,959...110,916,580
|
|
G |
Myl9 |
myosin light chain 9 |
increases expression |
ISO |
fenamidone results in increased expression of MYL9 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Myof |
myoferlin |
increases expression |
ISO |
fenamidone results in increased expression of MYOF mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:235,673,666...235,822,334
|
|
G |
Nab2 |
Ngfi-A binding protein 2 |
increases expression |
ISO |
fenamidone results in increased expression of NAB2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:63,497,589...63,504,105
Ensembl chr 7:63,497,589...63,503,989
|
|
G |
Nacc2 |
NACC family member 2 |
increases expression |
ISO |
fenamidone results in increased expression of NACC2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:8,879,952...8,946,660
Ensembl chr 3:8,883,065...8,946,660
|
|
G |
Nap1l2 |
nucleosome assembly protein 1-like 2 |
decreases expression |
ISO |
fenamidone results in decreased expression of NAP1L2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr X:68,174,051...68,176,449
Ensembl chr X:68,173,987...68,176,666
|
|
G |
Napb |
NSF attachment protein beta |
decreases expression |
ISO |
fenamidone results in decreased expression of NAPB mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:136,132,248...136,179,280
Ensembl chr 3:136,133,428...136,179,345
|
|
G |
Narf |
nuclear prelamin A recognition factor |
decreases expression |
ISO |
fenamidone results in decreased expression of NARF mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:106,519,508...106,537,494
Ensembl chr10:106,519,444...106,537,486
|
|
G |
Nek6 |
NIMA-related kinase 6 |
increases expression |
ISO |
fenamidone results in increased expression of NEK6 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:22,284,269...22,356,302
Ensembl chr 3:22,284,279...22,395,990
|
|
G |
Nes |
nestin |
increases expression |
ISO |
fenamidone results in increased expression of NES mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
|
|
G |
Neto1 |
neuropilin and tolloid like 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of NETO1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr18:79,635,633...79,753,913
Ensembl chr18:79,635,633...79,749,030
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
increases expression |
ISO |
fenamidone results in increased expression of NFKB2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
|
|
G |
Ngfr |
nerve growth factor receptor |
increases expression |
ISO |
fenamidone results in increased expression of TNFRSF10B mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nnt |
nicotinamide nucleotide transhydrogenase |
increases expression |
ISO |
fenamidone results in increased expression of NNT mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:51,411,413...51,505,125
Ensembl chr 2:51,411,413...51,504,823
|
|
G |
Notch1 |
notch receptor 1 |
increases expression |
ISO |
fenamidone results in increased expression of NOTCH1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Notch3 |
notch receptor 3 |
increases expression |
ISO |
fenamidone results in increased expression of NOTCH3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025
|
|
G |
Npr2 |
natriuretic peptide receptor 2 |
increases expression |
ISO |
fenamidone results in increased expression of NPR2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:57,883,171...57,901,590
Ensembl chr 5:57,883,171...57,901,580
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
fenamidone results in increased expression of NQO1 mRNA sulforaphane inhibits the reaction [fenamidone results in increased expression of NQO1 mRNA] |
CTD |
PMID:27029645 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nrg1 |
neuregulin 1 |
increases expression |
ISO |
fenamidone results in increased expression of NRG1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Nrxn3 |
neurexin 3 |
decreases expression |
ISO |
fenamidone results in decreased expression of NRXN3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:107,641,760...109,272,849
Ensembl chr 6:107,641,780...109,272,044
|
|
G |
Nuak2 |
NUAK family kinase 2 |
increases expression |
ISO |
fenamidone results in increased expression of NUAK2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr13:43,753,454...43,770,604
Ensembl chr13:43,753,832...43,770,604
|
|
G |
Nup93 |
nucleoporin 93 |
increases expression |
ISO |
fenamidone results in increased expression of NUP93 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr19:10,684,214...10,788,009
Ensembl chr19:10,682,075...10,788,026
|
|
G |
Nxph1 |
neurexophilin 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of NXPH1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:36,998,068...37,311,135
Ensembl chr 4:36,997,669...37,311,132
|
|
G |
Nxph2 |
neurexophilin 2 |
decreases expression |
ISO |
fenamidone results in decreased expression of NXPH2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:5,986,175...5,988,525
Ensembl chr 3:5,756,621...5,987,008
|
|
G |
Ostf1 |
osteoclast stimulating factor 1 |
increases expression |
ISO |
fenamidone results in increased expression of OSTF1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:216,002,037...216,049,226
Ensembl chr 1:216,002,044...216,049,221
|
|
G |
P2ry2 |
purinergic receptor P2Y2 |
increases expression |
ISO |
fenamidone results in increased expression of P2RY2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:155,352,050...155,367,423
Ensembl chr 1:155,351,165...155,367,632
|
|
G |
Palld |
palladin, cytoskeletal associated protein |
increases expression |
ISO |
fenamidone results in increased expression of PALLD mRNA |
CTD |
PMID:27029645 |
|
NCBI chr16:28,228,006...28,621,349
Ensembl chr16:27,981,354...28,621,337
|
|
G |
Parp3 |
poly (ADP-ribose) polymerase family, member 3 |
increases expression |
ISO |
fenamidone results in increased expression of PARP3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:107,111,010...107,117,073
Ensembl chr 8:107,111,012...107,116,782
|
|
G |
Pcdh19 |
protocadherin 19 |
decreases expression |
ISO |
fenamidone results in decreased expression of PCDH19 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr X:96,767,686...96,873,477
Ensembl chr X:96,771,947...96,873,524
|
|
G |
Pck2 |
phosphoenolpyruvate carboxykinase 2 (mitochondrial) |
increases expression |
ISO |
fenamidone results in increased expression of PCK2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr15:29,027,891...29,036,729
Ensembl chr15:29,027,894...29,037,283
|
|
G |
Pcyt1b |
phosphate cytidylyltransferase 1B, choline |
decreases expression |
ISO |
fenamidone results in decreased expression of PCYT1B mRNA |
CTD |
PMID:27029645 |
|
NCBI chr X:58,378,090...58,471,623
Ensembl chr X:58,378,116...58,468,935
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
increases expression |
ISO |
fenamidone results in increased expression of PDGFRB mRNA |
CTD |
PMID:27029645 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Pdlim2 |
PDZ and LIM domain 2 |
increases expression |
ISO |
fenamidone results in increased expression of PDLIM2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr15:45,235,421...45,250,187
Ensembl chr15:45,237,477...45,249,242
|
|
G |
Pdlim5 |
PDZ and LIM domain 5 |
increases expression |
ISO |
fenamidone results in increased expression of PDLIM5 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:230,952,251...231,120,329
Ensembl chr 2:230,952,248...231,120,275
|
|
G |
Pgm2l1 |
phosphoglucomutase 2-like 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of PGM2L1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:154,571,410...154,620,901
Ensembl chr 1:154,571,766...154,620,902
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
increases expression |
ISO |
fenamidone results in increased expression of PHGDH mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944
|
|
G |
Phlda3 |
pleckstrin homology-like domain, family A, member 3 |
increases expression |
ISO |
fenamidone results in increased expression of PHLDA3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335
|
|
G |
Phldb2 |
pleckstrin homology-like domain, family B, member 2 |
increases expression |
ISO |
fenamidone results in increased expression of PHLDB2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr11:54,859,173...55,078,212
Ensembl chr11:54,859,135...55,078,467
|
|
G |
Phyh |
phytanoyl-CoA 2-hydroxylase |
increases expression |
ISO |
fenamidone results in increased expression of PHYH mRNA |
CTD |
PMID:27029645 |
|
NCBI chr17:73,329,461...73,346,359
Ensembl chr17:73,329,082...73,346,409
|
|
G |
Piezo1 |
piezo-type mechanosensitive ion channel component 1 |
increases expression |
ISO |
fenamidone results in increased expression of PIEZO1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr19:50,544,580...50,606,812
Ensembl chr19:50,544,582...50,606,501
|
|
G |
Plau |
plasminogen activator, urokinase |
increases expression |
ISO |
fenamidone results in increased expression of PLAU mRNA |
CTD |
PMID:27029645 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plcb3 |
phospholipase C beta 3 |
increases expression |
ISO |
fenamidone results in increased expression of PLCB3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:204,143,257...204,160,384
Ensembl chr 1:204,144,956...204,160,228
|
|
G |
Plekha7 |
pleckstrin homology domain containing A7 |
increases expression |
ISO |
fenamidone results in increased expression of PLEKHA7 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:170,364,524...170,547,843
Ensembl chr 1:170,365,135...170,547,775
|
|
G |
Plekhg2 |
pleckstrin homology and RhoGEF domain containing G2 |
increases expression |
ISO |
fenamidone results in increased expression of PLEKHG2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:83,651,902...83,665,063
Ensembl chr 1:83,647,748...83,665,063
|
|
G |
Plekho2 |
pleckstrin homology domain containing O2 |
increases expression |
ISO |
fenamidone results in increased expression of PLEKHO2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:66,079,106...66,105,283
Ensembl chr 8:66,078,448...66,105,266
|
|
G |
Plxnb2 |
plexin B2 |
increases expression |
ISO |
fenamidone results in increased expression of PLXNB2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:120,232,276...120,258,385
Ensembl chr 7:120,232,331...120,258,330
|
|
G |
Pml |
PML nuclear body scaffold |
increases expression |
ISO |
fenamidone results in increased expression of PML mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Poglut3 |
protein O-glucosyltransferase 3 |
increases expression |
ISO |
fenamidone results in increased expression of POGLUT3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:53,777,614...53,795,404
Ensembl chr 8:53,777,785...53,795,399
|
|
G |
Ppm1e |
protein phosphatase, Mg2+/Mn2+ dependent, 1E |
decreases expression |
ISO |
fenamidone results in decreased expression of PPM1E mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:72,051,643...72,187,439
Ensembl chr10:72,055,208...72,187,282
|
|
G |
Prkcd |
protein kinase C, delta |
increases expression |
ISO |
fenamidone results in increased expression of PRKCD mRNA |
CTD |
PMID:27029645 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkcg |
protein kinase C, gamma |
decreases expression |
ISO |
fenamidone results in decreased expression of PRKCG mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:65,832,851...65,860,676
Ensembl chr 1:65,832,855...65,859,384
|
|
G |
Prkd1 |
protein kinase D1 |
increases expression |
ISO |
fenamidone results in increased expression of PRKD1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:67,725,193...68,039,002
Ensembl chr 6:67,725,905...68,039,042
|
|
G |
Prnd |
prion like protein doppel |
increases expression |
ISO |
fenamidone results in increased expression of PRND mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:119,213,462...119,218,742
Ensembl chr 3:119,213,429...119,218,745
|
|
G |
Prss23 |
serine protease 23 |
increases expression |
ISO |
fenamidone results in increased expression of PRSS23 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091
|
|
G |
Ptpn13 |
protein tyrosine phosphatase, non-receptor type 13 |
increases expression |
ISO |
fenamidone results in increased expression of PTPN13 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr14:6,108,202...6,282,619
Ensembl chr14:6,108,211...6,282,563
|
|
G |
Ptpn14 |
protein tyrosine phosphatase, non-receptor type 14 |
increases expression |
ISO |
fenamidone results in increased expression of PTPN14 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr13:101,268,258...101,420,508
Ensembl chr13:101,268,416...101,414,088
|
|
G |
Ptpn21 |
protein tyrosine phosphatase, non-receptor type 21 |
increases expression |
ISO |
fenamidone results in increased expression of PTPN21 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:117,933,066...117,998,095
Ensembl chr 6:117,933,066...117,998,095
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
increases expression |
ISO |
fenamidone results in increased expression of PTTG1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837
|
|
G |
Ptx3 |
pentraxin 3 |
increases expression |
ISO |
fenamidone results in increased expression of PTX3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
decreases expression |
ISO |
fenamidone results in decreased expression of RAB3B mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:123,629,562...123,697,410
Ensembl chr 5:123,644,423...123,697,401
|
|
G |
Rest |
RE1-silencing transcription factor |
increases expression |
ISO |
fenamidone results in increased expression of REST mRNA |
CTD |
PMID:27029645 |
|
NCBI chr14:30,859,109...30,879,828
Ensembl chr14:30,862,553...30,894,354
|
|
G |
Rgs7bp |
regulator of G-protein signaling 7 binding protein |
decreases expression |
ISO |
fenamidone results in decreased expression of RGS7BP mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:36,133,944...36,231,505
Ensembl chr 2:36,139,201...36,231,505
|
|
G |
Rhbdf2 |
rhomboid 5 homolog 2 |
increases expression |
ISO |
fenamidone results in increased expression of RHBDF2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:101,833,157...101,860,283
Ensembl chr10:101,833,157...101,860,283
|
|
G |
Rhoc |
ras homolog family member C |
increases expression |
ISO |
fenamidone results in increased expression of RHOC mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
|
|
G |
Rhod |
ras homolog family member D |
increases expression |
ISO |
fenamidone results in increased expression of RHOD mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:201,708,699...201,724,405
Ensembl chr 1:201,708,699...201,722,632
|
|
G |
Rhog |
ras homolog family member G |
increases expression |
ISO |
fenamidone results in increased expression of RHOG mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:156,618,713...156,630,710
Ensembl chr 1:156,615,349...156,631,257
|
|
G |
Rimkla |
ribosomal modification protein rimK-like family member A |
decreases expression |
ISO |
fenamidone results in decreased expression of RIMKLA mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:133,072,179...133,098,840
Ensembl chr 5:133,073,960...133,098,792
|
|
G |
Rph3a |
rabphilin 3A |
decreases expression |
ISO |
fenamidone results in decreased expression of RPH3A mRNA |
CTD |
PMID:27029645 |
|
NCBI chr12:35,542,389...35,618,901
Ensembl chr12:35,542,728...35,617,592
|
|
G |
Samd4a |
sterile alpha motif domain containing 4A |
increases expression |
ISO |
fenamidone results in increased expression of SAMD4 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr15:20,135,994...20,352,131
Ensembl chr15:20,134,377...20,348,380
|
|
G |
Sardh |
sarcosine dehydrogenase |
increases expression |
ISO |
fenamidone results in increased expression of SARDH mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:10,510,553...10,575,342
Ensembl chr 3:10,510,553...10,573,874
|
|
G |
Scarf2 |
scavenger receptor class F, member 2 |
increases expression |
ISO |
fenamidone results in increased expression of SCARF2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr11:83,175,956...83,187,415
Ensembl chr11:83,175,963...83,187,348
|
|
G |
Sdc1 |
syndecan 1 |
increases expression |
ISO |
fenamidone results in increased expression of SDC1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264
|
|
G |
Serpinf1 |
serpin family F member 1 |
increases expression |
ISO |
fenamidone results in increased expression of SERPINF1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646
|
|
G |
Serpinh1 |
serpin family H member 1 |
increases expression |
ISO |
fenamidone results in increased expression of SERPINH1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
|
|
G |
Serpini1 |
serpin family I member 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of SERPINI1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:160,346,403...160,433,135
Ensembl chr 2:160,346,758...160,433,135
|
|
G |
Sesn2 |
sestrin 2 |
increases expression |
ISO |
fenamidone results in increased expression of SESN2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Sgms2 |
sphingomyelin synthase 2 |
increases expression |
ISO |
fenamidone results in increased expression of SGMS2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:219,889,809...219,967,704
Ensembl chr 2:219,893,572...219,967,546
|
|
G |
Shank1 |
SH3 and multiple ankyrin repeat domains 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of SHANK1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:94,807,879...94,857,356
Ensembl chr 1:94,808,276...94,855,824
|
|
G |
Shc1 |
SHC adaptor protein 1 |
increases expression |
ISO |
fenamidone results in increased expression of SHC1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536
|
|
G |
Slc12a4 |
solute carrier family 12 member 4 |
increases expression |
ISO |
fenamidone results in increased expression of SLC12A4 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr19:33,838,418...33,860,369
Ensembl chr19:33,838,419...33,860,331
|
|
G |
Slc12a5 |
solute carrier family 12 member 5 |
decreases expression |
ISO |
fenamidone results in decreased expression of SLC12A5 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:153,696,517...153,735,801
Ensembl chr 3:153,696,517...153,735,765
|
|
G |
Slc12a7 |
solute carrier family 12 member 7 |
increases expression |
ISO |
fenamidone results in increased expression of SLC12A7 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:29,472,692...29,554,246
Ensembl chr 1:29,472,692...29,554,302
|
|
G |
Slc32a1 |
solute carrier family 32 member 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of SLC32A1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:147,267,373...147,271,842
Ensembl chr 3:147,267,373...147,271,844
|
|
G |
Slc4a2 |
solute carrier family 4 member 2 |
increases expression |
ISO |
fenamidone results in increased expression of SLC4A2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965
|
|
G |
Slc66a3 |
solute carrier family 66 member 3 |
increases expression |
ISO |
fenamidone results in increased expression of SLC66A3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:39,774,801...39,786,554
Ensembl chr 6:39,774,808...39,786,303
|
|
G |
Slc8a3 |
solute carrier family 8 member A3 |
decreases expression |
ISO |
fenamidone results in decreased expression of SLC8A3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:100,874,359...101,007,989
Ensembl chr 6:100,874,369...101,007,508
|
|
G |
Smim10l2a |
small integral membrane protein 10 like 2A |
decreases expression |
ISO |
fenamidone results in decreased expression of SMIM10L2A mRNA |
CTD |
PMID:27029645 |
|
NCBI chr X:134,151,325...134,154,647
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3 |
decreases expression |
ISO |
fenamidone results in decreased expression of SMPD3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749
|
|
G |
Snx33 |
sorting nexin 33 |
increases expression |
ISO |
fenamidone results in increased expression of SNX33 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:57,315,861...57,328,522
Ensembl chr 8:57,317,161...57,327,538
|
|
G |
Sorbs3 |
sorbin and SH3 domain containing 3 |
increases expression |
ISO |
fenamidone results in increased expression of SORBS3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr15:45,252,921...45,284,758
Ensembl chr15:45,253,379...45,284,758
|
|
G |
Sorl1 |
sortilin related receptor 1 |
increases expression |
ISO |
fenamidone results in increased expression of SORL1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
increases expression |
ISO |
fenamidone results in increased expression of SPARC mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Spock3 |
SPARC/osteonectin, cwcv and kazal like domains proteoglycan 3 |
decreases expression |
ISO |
fenamidone results in decreased expression of SPOCK3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr16:26,382,895...26,815,943
Ensembl chr16:26,383,383...26,815,205
|
|
G |
Sprn |
shadow of prion protein |
decreases expression |
ISO |
fenamidone results in decreased expression of SPRN mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:194,944,602...194,948,448
Ensembl chr 1:194,943,826...194,948,460
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
ISO |
fenamidone results in increased expression of SRXN1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Ssc5d |
scavenger receptor cysteine rich family member with 5 domains |
increases expression |
ISO |
fenamidone results in increased expression of SSC5D mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:68,891,942...68,910,462
Ensembl chr 1:68,891,949...68,909,743
|
|
G |
St8sia3 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 |
decreases expression |
ISO |
fenamidone results in decreased expression of ST8SIA3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr18:57,754,349...57,760,839
Ensembl chr18:57,754,347...57,760,839
|
|
G |
Stk17b |
serine/threonine kinase 17b |
increases expression |
ISO |
fenamidone results in increased expression of STK17B mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 9:55,307,485...55,338,085
Ensembl chr 9:55,307,668...55,338,031
|
|
G |
Ston1 |
stonin 1 |
increases expression |
ISO |
fenamidone results in increased expression of STON1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:5,843,186...5,892,557
Ensembl chr 6:5,843,185...5,892,449
|
|
G |
Sun2 |
Sad1 and UNC84 domain containing 2 |
increases expression |
ISO |
fenamidone results in increased expression of SUN2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:111,275,374...111,292,565
Ensembl chr 7:111,275,380...111,292,553
|
|
G |
Sv2b |
synaptic vesicle glycoprotein 2b |
decreases expression |
ISO |
fenamidone results in decreased expression of SV2B mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:128,978,471...129,152,479
Ensembl chr 1:128,978,473...129,152,479
|
|
G |
Svil |
supervillin |
increases expression |
ISO |
fenamidone results in increased expression of SVIL mRNA |
CTD |
PMID:27029645 |
|
NCBI chr17:52,648,502...52,844,114
Ensembl chr17:52,648,502...52,793,404
|
|
G |
Swap70 |
switching B-cell complex subunit SWAP70 |
increases expression |
ISO |
fenamidone results in increased expression of SWAP70 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:164,267,588...164,328,796
Ensembl chr 1:164,267,609...164,328,794
|
|
G |
Syde1 |
synapse defective Rho GTPase homolog 1 |
increases expression |
ISO |
fenamidone results in increased expression of SYDE1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:11,032,931...11,038,917
Ensembl chr 7:11,032,898...11,039,869
|
|
G |
Syn1 |
synapsin I |
decreases expression |
ISO |
fenamidone results in decreased expression of SYN1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396
|
|
G |
Sync |
syncoilin, intermediate filament protein |
increases expression |
ISO |
fenamidone results in increased expression of SYNC mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:141,631,837...141,656,184
Ensembl chr 5:141,632,367...141,688,659
|
|
G |
Syt1 |
synaptotagmin 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of SYT1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:43,813,204...44,358,020
Ensembl chr 7:43,815,785...44,357,803
|
|
G |
Tagln |
transgelin |
increases expression |
ISO |
fenamidone results in increased expression of TAGLN mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tcirg1 |
T-cell immune regulator 1, ATPase H+ transporting V0 subunit A3 |
increases expression |
ISO |
fenamidone results in increased expression of TCIRG1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:201,127,034...201,138,787
Ensembl chr 1:201,127,034...201,138,742
|
|
G |
Tead1 |
TEA domain transcription factor 1 |
increases expression |
ISO |
fenamidone results in increased expression of TEAD1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:166,791,900...167,010,591
Ensembl chr 1:166,792,628...167,003,369
|
|
G |
Tead2 |
TEA domain transcription factor 2 |
increases expression |
ISO |
fenamidone results in increased expression of TEAD2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:95,702,366...95,719,186
Ensembl chr 1:95,703,005...95,719,186
|
|
G |
Tent5b |
terminal nucleotidyltransferase 5B |
increases expression |
ISO |
fenamidone results in increased expression of TENT5B mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:145,695,358...145,702,668
Ensembl chr 5:145,695,362...145,706,073 Ensembl chr11:145,695,362...145,706,073
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression |
ISO |
fenamidone results in increased expression of TGFB2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
increases expression |
ISO |
fenamidone results in increased expression of TGFB3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
|
|
G |
Thbs1 |
thrombospondin 1 |
increases expression |
ISO |
fenamidone results in increased expression of THBS1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
increases expression |
ISO |
fenamidone results in increased expression of TIMP3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:17,521,919...17,571,839
|
|
G |
Tinagl1 |
tubulointerstitial nephritis antigen-like 1 |
increases expression |
ISO |
fenamidone results in increased expression of TINAGL1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:142,513,710...142,523,730
Ensembl chr 5:142,513,714...142,523,720
|
|
G |
Tjap1 |
tight junction associated protein 1 |
increases expression |
ISO |
fenamidone results in increased expression of TJAP1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 9:14,701,418...14,725,623
Ensembl chr 9:14,701,468...14,725,751
|
|
G |
Tln1 |
talin 1 |
increases expression |
ISO |
fenamidone results in increased expression of TLN1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:57,787,670...57,817,900
Ensembl chr 5:57,787,943...57,817,900
|
|
G |
Tmbim1 |
transmembrane BAX inhibitor motif containing 1 |
increases expression |
ISO |
fenamidone results in increased expression of TMBIM1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 9:75,871,835...75,889,366
Ensembl chr 9:75,871,835...75,889,069
|
|
G |
Tmem178a |
transmembrane protein 178A |
decreases expression |
ISO |
fenamidone results in decreased expression of TMEM178 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:14,004,629...14,063,677
Ensembl chr 6:14,004,630...14,063,549
|
|
G |
Tnc |
tenascin C |
increases expression |
ISO |
fenamidone results in increased expression of TNC mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624
|
|
G |
Tnfrsf12a |
TNF receptor superfamily member 12A |
increases expression |
ISO |
fenamidone results in increased expression of TNFRSF12A mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:12,707,077...12,709,071
Ensembl chr10:12,689,890...12,709,045
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
ISO |
fenamidone results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tns1 |
tensin 1 |
increases expression |
ISO |
fenamidone results in increased expression of TNS1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 9:75,491,886...75,702,853
Ensembl chr 9:75,495,814...75,703,225
|
|
G |
Tns3 |
tensin 3 |
increases expression |
ISO |
fenamidone results in increased expression of TNS3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr14:83,173,649...83,405,671
Ensembl chr14:83,173,649...83,405,998
|
|
G |
Tpm4 |
tropomyosin 4 |
increases expression |
ISO |
fenamidone results in increased expression of TPM4 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr16:17,684,415...17,698,456
Ensembl chr16:17,683,195...17,705,984
|
|
G |
Tpp1 |
tripeptidyl peptidase 1 |
increases expression |
ISO |
fenamidone results in increased expression of TPP1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:160,097,984...160,104,108
Ensembl chr 1:160,096,833...160,104,129
|
|
G |
Ttyh2 |
tweety family member 2 |
increases expression |
ISO |
fenamidone results in increased expression of TTYH2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:99,709,063...99,753,449
Ensembl chr10:99,709,007...99,753,444
|
|
G |
Tuba4a |
tubulin, alpha 4A |
decreases expression |
ISO |
fenamidone results in decreased expression of TUBA4A mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 9:76,709,617...76,714,327
Ensembl chr 9:76,709,614...76,713,918
|
|
G |
Tubb6 |
tubulin, beta 6 class V |
increases expression |
ISO |
fenamidone results in increased expression of TUBB6 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr18:60,943,394...60,953,031
Ensembl chr18:60,943,375...60,954,418
|
|
G |
Tuft1 |
tuftelin 1 |
increases expression |
ISO |
fenamidone results in increased expression of TUFT1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:182,259,457...182,306,296
Ensembl chr 2:182,260,398...182,306,192
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
fenamidone results in increased expression of TXNRD1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Uap1l1 |
UDP-N-acetylglucosamine pyrophosphorylase 1 like 1 |
increases expression |
ISO |
fenamidone results in increased expression of UAP1L1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 3:8,172,335...8,180,505
Ensembl chr 3:8,173,216...8,180,443
|
|
G |
Utrn |
utrophin |
increases expression |
ISO |
fenamidone results in increased expression of UTRN mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:6,720,854...7,224,313
Ensembl chr 1:6,722,594...7,224,313
|
|
G |
Vasn |
vasorin |
increases expression |
ISO |
fenamidone results in increased expression of VASN mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:10,917,750...10,928,259
Ensembl chr10:10,917,605...10,928,357
|
|
G |
Vcl |
vinculin |
increases expression |
ISO |
fenamidone results in increased expression of VCL mRNA |
CTD |
PMID:27029645 |
|
NCBI chr15:3,265,776...3,355,586
Ensembl chr15:3,265,815...3,355,606
|
|
G |
Vgll3 |
vestigial-like family member 3 |
increases expression |
ISO |
fenamidone results in increased expression of VGLL3 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr11:3,642,993...3,692,590
Ensembl chr11:3,643,069...3,689,140
|
|
G |
Vim |
vimentin |
increases expression |
ISO |
fenamidone results in increased expression of VIM mRNA |
CTD |
PMID:27029645 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Vsnl1 |
visinin-like 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of VSNL1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:34,038,641...34,159,479
Ensembl chr 6:34,038,642...34,159,479
|
|
G |
Wasf2 |
WASP family member 2 |
increases expression |
ISO |
fenamidone results in increased expression of WASF2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:145,336,817...145,402,041
Ensembl chr 5:145,336,842...145,399,242
|
|
G |
Wnt9a |
Wnt family member 9A |
increases expression |
ISO |
fenamidone results in increased expression of WNT9A mRNA |
CTD |
PMID:27029645 |
|
NCBI chr10:44,094,140...44,121,134
Ensembl chr10:44,094,140...44,121,133
|
|
G |
Xkr4 |
XK related 4 |
decreases expression |
ISO |
fenamidone results in decreased expression of XKR4 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 5:15,896,818...16,297,733
Ensembl chr 5:15,895,863...16,282,962
|
|
G |
Yif1a |
Yip1 interacting factor homolog A, membrane trafficking protein |
increases expression |
ISO |
fenamidone results in increased expression of YIF1A mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 1:202,394,923...202,399,125
Ensembl chr 1:202,394,897...202,399,427
|
|
G |
Ypel1 |
yippee-like 1 |
decreases expression |
ISO |
fenamidone results in decreased expression of YPEL1 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr11:83,921,799...83,936,409
|
|
G |
Zbtb7b |
zinc finger and BTB domain containing 7B |
increases expression |
ISO |
fenamidone results in increased expression of ZBTB7B mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 2:174,795,831...174,811,980
Ensembl chr 2:174,797,453...174,814,236
|
|
G |
Zfp36l2 |
zinc finger protein 36, C3H type-like 2 |
increases expression |
ISO |
fenamidone results in increased expression of ZFP36L2 mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 6:10,490,032...10,494,073
Ensembl chr 6:10,490,032...10,494,064
|
|
G |
Zyx |
zyxin |
increases expression |
ISO |
fenamidone results in increased expression of ZYX mRNA |
CTD |
PMID:27029645 |
|
NCBI chr 4:71,236,767...71,246,553
Ensembl chr 4:71,237,451...71,246,553
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO EXP |
iprodione binds to and results in increased activity of AHR protein |
CTD |
PMID:14636698 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of ALDH2 mRNA; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of and results in decreased activity of ALDH2 protein |
CTD |
PMID:34830855 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Anxa10 |
annexin A10 |
increases expression |
ISO |
iprodione results in increased expression of ANXA10 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648
|
|
G |
Ar |
androgen receptor |
multiple interactions affects binding |
ISO |
[iprodione binds to and results in decreased activity of AR protein] inhibits the reaction [Metribolone binds to AR protein]; iprodione inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; iprodione inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein] iprodione binds to AR protein |
CTD |
PMID:19564212 PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
EXP |
iprodione results in decreased expression of BCL2 protein Chlorpyrifos promotes the reaction [iprodione results in decreased expression of BCL2 protein]; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of BCL2 protein] |
CTD |
PMID:33586219 PMID:34060014 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
EXP |
iprodione results in increased expression of CASP3 protein Chlorpyrifos promotes the reaction [iprodione results in increased expression of CASP3 protein]; iprodione promotes the reaction [Chlorpyrifos results in increased expression of CASP3 protein] |
CTD |
PMID:33586219 PMID:34060014 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] results in decreased expression of CDH1 protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in decreased expression of CDH1 protein |
CTD |
PMID:34503147 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cldn11 |
claudin 11 |
increases expression multiple interactions |
EXP |
iprodione results in increased expression of CLDN11 protein [carbendazim co-treated with iprodione] results in decreased expression of CLDN11 protein |
CTD |
PMID:28576679 |
|
NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases activity |
ISO |
iprodione results in increased activity of CYP19A1 protein |
CTD |
PMID:11884232 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
iprodione results in increased expression of CYP1A1 mRNA; iprodione results in increased expression of CYP1A1 protein |
CTD |
PMID:16696176 PMID:32194361 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases expression |
ISO |
iprodione results in decreased expression of CYP2C19 protein |
CTD |
PMID:32194361 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased expression of CYP3A4 mRNA |
CTD |
PMID:25028461 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
iprodione results in decreased expression of CYP7A1 protein |
CTD |
PMID:32194361 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
iprodione results in increased expression of DDIT3 mRNA |
CTD |
PMID:16696176 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
iprodione binds to and results in increased activity of ESR1 protein |
CTD |
PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
iprodione binds to and results in increased activity of ESR2 protein |
CTD |
PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
iprodione results in increased expression of FOS mRNA |
CTD |
PMID:16696176 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions decreases expression |
EXP |
Chlorpyrifos inhibits the reaction [iprodione results in decreased expression of FSHB protein]; iprodione inhibits the reaction [Chlorpyrifos results in decreased expression of FSHB protein]; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of FSHB protein] |
CTD |
PMID:33586219 PMID:34060014 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
iprodione results in increased expression of GADD45A mRNA |
CTD |
PMID:16696176 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
EXP |
[carbendazim co-treated with iprodione] results in decreased expression of GJA1 protein |
CTD |
PMID:28576679 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression |
ISO |
iprodione results in increased expression of GSTA2 mRNA |
CTD |
PMID:16696176 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
[fludioxonil co-treated with cyprodinil co-treated with procymidone co-treated with iprodione co-treated with cyhalothrin] results in increased phosphorylation of H2AX protein; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in increased expression of H2AX protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] results in increased expression of H2AX protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased expression of H2AX protein |
CTD |
PMID:22389207 PMID:34503147 PMID:34830855 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
multiple interactions decreases expression |
EXP |
[Chlorpyrifos co-treated with iprodione] results in decreased expression of HSD17B3 mRNA; [iprodione co-treated with Chlorpyrifos] results in decreased expression of HSD17B3 mRNA iprodione results in decreased expression of HSD17B3 mRNA |
CTD |
PMID:33586219 PMID:34060014 |
|
NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
iprodione results in increased expression of HSPA5 mRNA |
CTD |
PMID:16696176 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions decreases expression |
EXP |
Chlorpyrifos inhibits the reaction [iprodione results in decreased expression of LHB protein]; iprodione inhibits the reaction [Chlorpyrifos results in decreased expression of LHB protein] |
CTD |
PMID:34060014 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] results in increased activity of NR1I2 protein; iprodione binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:25028461 PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
decreases expression multiple interactions |
EXP |
iprodione results in decreased expression of NR5A1 mRNA [iprodione co-treated with Chlorpyrifos] results in decreased expression of NR5A1 mRNA; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of NR5A1 mRNA] |
CTD |
PMID:33586219 PMID:34060014 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases activity multiple interactions |
ISO |
iprodione results in increased activity of PPARG protein iprodione binds to and results in increased activity of PPARG protein |
CTD |
PMID:20143881 PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression multiple interactions |
EXP |
iprodione results in decreased expression of PPARGC1A mRNA Chlorpyrifos promotes the reaction [iprodione results in decreased expression of PPARGC1A mRNA]; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:33586219 PMID:34060014 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
EXP |
[iprodione co-treated with Chlorpyrifos] results in decreased expression of SIRT1 mRNA; iprodione promotes the reaction [Chlorpyrifos results in decreased expression of SIRT1 mRNA] iprodione results in decreased expression of SIRT1 mRNA |
CTD |
PMID:33586219 PMID:34060014 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Stmn1 |
stathmin 1 |
increases expression |
EXP |
iprodione results in increased expression of STMN1 mRNA |
CTD |
PMID:28576679 |
|
NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions decreases expression |
EXP |
[Chlorpyrifos co-treated with iprodione] results in decreased expression of TERT mRNA; [iprodione co-treated with Chlorpyrifos] results in decreased expression of TERT mRNA iprodione results in decreased expression of TERT mRNA |
CTD |
PMID:33586219 PMID:34060014 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
iprodione binds to and results in increased activity of THRA protein |
CTD |
PMID:33049310 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
iprodione binds to and results in increased activity of THRB protein |
CTD |
PMID:33049310 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [iprodione inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; iprodione inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:33226166 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] affects the expression of TP53BP1 protein; [procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin] affects the expression of TP53BP1 protein |
CTD |
PMID:34503147 |
|
NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCB11 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
ISO EXP |
prochloraz results in increased expression of ABCB1A mRNA; prochloraz results in increased expression of ABCB1A protein [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCB1A mRNA |
CTD |
PMID:27028005 PMID:29038839 PMID:33150952 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
multiple interactions |
ISO |
prochloraz results in increased expression of and results in increased activity of ABCB1B protein |
CTD |
PMID:27028005 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression multiple interactions |
EXP |
prochloraz results in increased expression of ABCC2 mRNA [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCC2 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions increases expression |
EXP ISO |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ABCC3 mRNA prochloraz results in increased expression of ABCC3 protein |
CTD |
PMID:29038839 PMID:33150952 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
decreases expression |
ISO |
prochloraz results in decreased expression of ABCG2 mRNA |
CTD |
PMID:27028005 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Aco1 |
aconitase 1 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ACO1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
|
|
G |
Acot3 |
acyl-CoA thioesterase 3 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ACOT3 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 6:103,682,518...103,688,735
Ensembl chr 6:103,682,596...103,688,427 Ensembl chr 6:103,682,596...103,688,427
|
|
G |
Acot9 |
acyl-CoA thioesterase 9 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ACOT9 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr X:40,073,197...40,123,573
Ensembl chr X:40,064,810...40,123,559
|
|
G |
Actn1 |
actinin, alpha 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ACTN1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G |
Acvr2b |
activin A receptor type 2B |
decreases expression multiple interactions |
EXP |
prochloraz results in decreased expression of SCGB2A2 mRNA prochloraz inhibits the reaction [Testosterone Propionate results in increased expression of SCGB2A2 mRNA] |
CTD |
PMID:12377983 PMID:15519604 PMID:16375936 |
|
NCBI chr 8:119,138,901...119,178,477
Ensembl chr 8:119,138,812...119,170,458
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
increases expression |
EXP |
prochloraz results in increased expression of ADH4 mRNA |
CTD |
PMID:25182419 |
|
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression |
ISO |
prochloraz results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:30879083 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases expression |
ISO EXP |
prochloraz binds to and results in increased activity of AHR protein prochloraz results in increased expression of AHR mRNA |
CTD |
PMID:14636698 PMID:18835618 PMID:25182419 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression multiple interactions |
EXP |
prochloraz results in increased expression of ALDH1A1 mRNA [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:25182419 PMID:29038839 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Anxa10 |
annexin A10 |
increases expression |
ISO |
prochloraz results in increased expression of ANXA10 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
multiple interactions increases expression |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of APEX1 mRNA prochloraz results in increased expression of APEX1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Ar |
androgen receptor |
decreases activity multiple interactions affects binding |
ISO EXP |
prochloraz results in decreased activity of AR protein prochloraz binds to and results in decreased activity of AR protein; prochloraz inhibits the reaction [Metribolone binds to AR protein]; prochloraz inhibits the reaction [Metribolone results in increased expression of AR mRNA] prochloraz binds to AR protein [procymidone co-treated with prochloraz co-treated with vinclozolin] inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; [propiconazole co-treated with prochloraz co-treated with tebuconazole] inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; [propiconazole co-treated with prochloraz] inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; [tebuconazole co-treated with prochloraz] inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; Dihydrotestosterone inhibits the reaction [prochloraz results in increased activity of AR protein]; prochloraz binds to and results in decreased activity of AR protein; prochloraz inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; prochloraz inhibits the reaction [Dihydrotestosterone affects the localization of and results in increased phosphorylation of AR protein]; prochloraz inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; prochloraz inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; prochloraz inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:14687758 PMID:15064155 PMID:15519604 PMID:15673607 PMID:18315717 PMID:18324785 PMID:19833195 PMID:20438827 PMID:20821581 PMID:21251949 PMID:21310686 PMID:25324206 PMID:26602169 PMID:33049310 More...
|
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arg1 |
arginase 1 |
decreases expression |
ISO |
prochloraz results in decreased expression of ARG1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
affects expression |
EXP |
prochloraz affects the expression of ARNT mRNA |
CTD |
PMID:25182419 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ASNS mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atm |
ATM serine/threonine kinase |
increases expression |
EXP |
prochloraz results in increased expression of ATM mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
increases expression |
EXP |
prochloraz results in increased expression of ATP8B1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of BACE1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bace2 |
beta-secretase 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of BACE2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr11:36,707,447...36,789,550
Ensembl chr11:36,707,458...36,789,546
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
prochloraz inhibits the reaction [Testosterone results in increased expression of BAX mRNA] |
CTD |
PMID:31152826 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression |
EXP |
prochloraz results in increased expression of BCL2L1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression |
EXP |
prochloraz results in increased expression of BCL2L11 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of BDNF mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bsn |
bassoon (presynaptic cytomatrix protein) |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of BSN mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 8:108,784,849...108,875,819
Ensembl chr 8:108,788,542...108,875,819
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1A mRNA |
CTD |
PMID:25607892 |
|
NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
|
|
G |
Cacna1b |
calcium voltage-gated channel subunit alpha1 B |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1B mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:7,380,892...7,546,104
Ensembl chr 3:7,380,922...7,546,091
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1C mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
|
|
G |
Cacna1d |
calcium voltage-gated channel subunit alpha1 D |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1D mRNA |
CTD |
PMID:25607892 |
|
NCBI chr16:5,227,157...5,521,163
Ensembl chr16:5,228,306...5,668,215
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNA1G mRNA |
CTD |
PMID:25607892 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNA1I mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688
|
|
G |
Cacna2d3 |
calcium voltage-gated channel auxiliary subunit alpha2delta 3 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CACNA2D3 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr16:4,098,439...4,912,498
Ensembl chr16:4,098,445...4,912,351
|
|
G |
Cacnb1 |
calcium voltage-gated channel auxiliary subunit beta 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNB1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr10:82,998,182...83,018,838
Ensembl chr10:82,998,182...83,018,694
|
|
G |
Cacnb3 |
calcium voltage-gated channel auxiliary subunit beta 3 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNB3 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:129,784,799...129,797,074
Ensembl chr 7:129,783,674...129,797,074
|
|
G |
Cacng2 |
calcium voltage-gated channel auxiliary subunit gamma 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:109,572,838...109,698,516
Ensembl chr 7:109,574,459...109,697,227
|
|
G |
Cacng6 |
calcium voltage-gated channel auxiliary subunit gamma 6 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CACNG6 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:65,732,910...65,747,377
Ensembl chr 1:65,732,632...65,747,341
|
|
G |
Cacng7 |
calcium voltage-gated channel auxiliary subunit gamma 7 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CACNG7 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:65,800,059...65,831,246
Ensembl chr 1:65,800,355...65,831,006
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CADM1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CAMK2B mRNA |
CTD |
PMID:25607892 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CAMK2G mRNA |
CTD |
PMID:25607892 |
|
NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CD36 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd44 |
CD44 molecule |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CD44 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd81 |
Cd81 molecule |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CD81 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:198,235,861...198,251,660
Ensembl chr 1:198,241,484...198,251,660
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions decreases expression |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in decreased expression of CDKN1A mRNA prochloraz results in decreased expression of CDKN1A mRNA |
CTD |
PMID:29038839 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Ces2c |
carboxylesterase 2C |
increases expression multiple interactions |
EXP |
prochloraz results in increased expression of CES2C mRNA [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CES2C mRNA |
CTD |
PMID:25182419 PMID:29038839 |
|
NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790
|
|
G |
Chga |
chromogranin A |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of CHGA mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CPT2 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
ISO |
prochloraz results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:19733639 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
decreases expression multiple interactions |
ISO EXP |
prochloraz results in decreased expression of CYP11B1 mRNA [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in decreased expression of CYP11B1 mRNA |
CTD |
PMID:19733639 PMID:28454766 |
|
NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases activity multiple interactions increases expression decreases expression |
ISO EXP |
prochloraz results in decreased activity of CYP17A1 protein [prochloraz results in decreased activity of CYP17A1 protein] which results in decreased chemical synthesis of Testosterone prochloraz results in increased expression of CYP17A1 mRNA; prochloraz results in increased expression of CYP17A1 protein prochloraz results in decreased expression of and results in decreased activity of CYP17A1 protein prochloraz results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:16375936 PMID:17234647 PMID:17369198 PMID:19733639 PMID:25324206 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity increases activity multiple interactions increases expression |
ISO EXP |
prochloraz results in decreased activity of CYP19A1 protein prochloraz results in increased activity of CYP19A1 protein [prochloraz co-treated with Chlorpyrifos co-treated with triflusulfuron-methyl] results in increased expression of CYP19A1 mRNA; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased expression of CYP19A1 mRNA prochloraz results in increased expression of CYP19A1 mRNA [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:10806373 PMID:11884232 PMID:15554355 PMID:16996190 PMID:20087668 PMID:25233012 PMID:25607892 PMID:25765474 PMID:37551828 More...
|
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity increases expression multiple interactions |
EXP ISO |
prochloraz results in increased activity of CYP1A1 protein prochloraz results in increased expression of CYP1A1 mRNA; prochloraz results in increased expression of CYP1A1 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [prochloraz results in increased expression of CYP1A1 mRNA]; [NR1I2 protein co-treated with NR1I3 protein co-treated with prochloraz] results in increased expression of CYP1A1 mRNA [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased activity of CYP1A1 protein; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased expression of CYP1A1 mRNA |
CTD |
PMID:20035023 PMID:21784029 PMID:25182419 PMID:25233012 PMID:25765474 PMID:28058446 PMID:29038839 PMID:32194361 PMID:33150952 More...
|
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO EXP |
prochloraz results in increased expression of CYP1A2 mRNA; prochloraz results in increased expression of CYP1A2 protein |
CTD |
PMID:21784029 PMID:25182419 PMID:33150952 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
prochloraz results in increased expression of CYP1B1 mRNA; prochloraz results in increased expression of CYP1B1 protein |
CTD |
PMID:20035023 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases activity increases expression multiple interactions |
EXP |
prochloraz results in increased activity of CYP2B1 protein prochloraz results in increased expression of CYP2B1 mRNA [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased activity of CYP2B1 protein; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased expression of CYP2B1 mRNA |
CTD |
PMID:25182419 PMID:29038839 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b15 |
cytochrome P450, family 2, subfamily b, polypeptide 15 |
increases expression |
EXP |
prochloraz results in increased expression of CYP2B15 mRNA |
CTD |
PMID:25182419 |
|
NCBI chr 1:82,094,188...82,106,492
Ensembl chr 1:82,094,180...82,106,492
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression multiple interactions |
EXP |
prochloraz results in increased expression of CYP2B2 mRNA [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CYP2B2 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases expression |
ISO |
[NR1I2 protein co-treated with NR1I3 protein] affects the reaction [prochloraz results in increased expression of CYP2B10 protein] prochloraz results in increased expression of CYP2B6 mRNA; prochloraz results in increased expression of CYP2B6 protein prochloraz results in increased expression of CYP2B10 mRNA; prochloraz results in increased expression of CYP2B10 protein |
CTD |
PMID:28058446 PMID:33150952 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases expression |
EXP |
prochloraz results in increased expression of CYP2C11 protein |
CTD |
PMID:33150952 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c13 |
cytochrome P450, family 2, subfamily c, polypeptide 13 |
increases expression |
EXP |
prochloraz results in increased expression of CYP2C13 protein |
CTD |
PMID:33150952 |
|
NCBI chr 1:238,786,764...238,867,195
Ensembl chr 1:238,786,765...238,867,191
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
increases expression |
ISO EXP |
prochloraz results in increased expression of CYP2C55 protein |
CTD |
PMID:33150952 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases expression increases expression |
ISO |
prochloraz results in decreased expression of CYP2C19 protein prochloraz results in increased expression of CYP2C29 protein |
CTD |
PMID:32194361 PMID:33150952 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases expression |
ISO |
prochloraz results in decreased expression of CYP2D6 mRNA |
CTD |
PMID:20035023 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression |
ISO |
prochloraz results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:20035023 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
decreases expression |
ISO |
prochloraz results in decreased expression of CYP2J2 mRNA |
CTD |
PMID:20035023 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp2u1 |
cytochrome P450, family 2, subfamily u, polypeptide 1 |
decreases expression |
ISO |
prochloraz results in decreased expression of CYP2U1 mRNA |
CTD |
PMID:20035023 |
|
NCBI chr 2:219,849,403...219,866,959
Ensembl chr 2:219,849,407...219,866,882
|
|
G |
Cyp3a18 |
cytochrome P450, family 3, subfamily a, polypeptide 18 |
increases expression |
EXP |
prochloraz results in increased expression of CYP3A18 protein |
CTD |
PMID:33150952 |
|
NCBI chr12:8,880,509...8,930,382
Ensembl chr12:8,880,528...8,930,381
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases expression |
EXP ISO |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of CYP3A2 mRNA prochloraz results in increased expression of CYP3A4 protein [Amiodarone co-treated with Benzoic Acid co-treated with cyproconazole co-treated with flusilazole co-treated with enilconazole co-treated with prochloraz co-treated with propiconazole co-treated with tebuconazole] results in increased expression of CYP3A4 protein |
CTD |
PMID:29038839 PMID:33150952 PMID:34273450 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression increases activity multiple interactions |
EXP |
prochloraz results in increased expression of CYP3A23-3A1 mRNA prochloraz results in increased activity of CYP3A23-3A1 protein [prochloraz co-treated with cyproconazole co-treated with epoxiconazole] results in increased expression of CYP3A23-3A1 mRNA; [prochloraz co-treated with epoxiconazole co-treated with cyproconazole] results in increased activity of CYP3A23-3A1 protein |
CTD |
PMID:25182419 PMID:29038839 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression |
EXP |
prochloraz results in increased expression of CYP3A9 protein |
CTD |
PMID:33150952 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases activity |
ISO |
prochloraz results in decreased activity of CYP51A1 protein |
CTD |
PMID:16989930 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410 Ensembl chr 6:30,036,865...30,055,410
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
prochloraz results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Dcc |
DCC netrin 1 receptor |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DCC mRNA |
CTD |
PMID:25607892 |
|
NCBI chr18:64,868,987...65,972,783
Ensembl chr18:64,873,898...65,972,740
|
|
G |
Dlg1 |
discs large MAGUK scaffold protein 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DLG1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of DLG4 mRNA; [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DLG4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153
|
|
G |
Dlgap3 |
DLG associated protein 3 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DLGAP3 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 5:139,491,972...139,562,625
Ensembl chr 5:139,492,947...139,562,625
|
|
G |
Dlgap4 |
DLG associated protein 4 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DLGAP4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:145,124,189...145,271,791
Ensembl chr 3:145,175,479...145,270,490
|
|
G |
Doc2a |
double C2 domain alpha |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DOC2A mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:181,457,415...181,462,528
Ensembl chr 1:181,458,390...181,462,030
|
|
G |
Dpp10 |
dipeptidyl peptidase like 10 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DPP10 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr13:34,584,420...36,269,292
Ensembl chr13:34,595,868...36,269,292
|
|
G |
Dpp6 |
dipeptidyl peptidase like 6 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of DPP6 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 4:7,589,386...8,508,666
Ensembl chr 4:7,591,009...8,508,532
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of DPYD mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGF mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of EGFR mRNA |
CTD |
PMID:25607892 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of EHHADH mRNA |
CTD |
PMID:29038839 |
|
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of EIF2AK3 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of EP300 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB4 mRNA; [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of ERBB4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of ERCC1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Ercc2 |
ERCC excision repair 2, TFIIH core complex helicase subunit |
increases expression |
EXP |
prochloraz results in increased expression of ERCC2 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression |
ISO |
Fulvestrant inhibits the reaction [prochloraz results in decreased expression of ESR1 mRNA]; prochloraz binds to and results in increased activity of ESR1 protein; prochloraz inhibits the reaction [Estradiol results in decreased expression of ESR1 mRNA] prochloraz results in decreased expression of ESR1 mRNA; prochloraz results in decreased expression of ESR1 protein |
CTD |
PMID:15130599 PMID:15261991 PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions decreases expression |
ISO |
Fulvestrant inhibits the reaction [prochloraz results in decreased expression of ESR2 mRNA]; prochloraz binds to and results in increased activity of ESR2 protein; prochloraz promotes the reaction [Estradiol results in increased expression of ESR2 mRNA] |
CTD |
PMID:15130599 PMID:15261991 PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
ISO |
prochloraz results in decreased expression of FABP4 mRNA |
CTD |
PMID:30879083 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of FAS mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FMR1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of FYN mRNA |
CTD |
PMID:25607892 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
prochloraz results in decreased expression of G6PC1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gabra4 |
gamma-aminobutyric acid type A receptor subunit alpha 4 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GABRA4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr14:36,590,782...36,667,724
Ensembl chr14:36,590,782...36,665,844
|
|
G |
Gabrb1 |
gamma-aminobutyric acid type A receptor subunit beta1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GABRB1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GDNF mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
increases expression |
EXP |
prochloraz results in increased expression of GGT1 mRNA |
CTD |
PMID:25182419 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Gls |
glutaminase |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GLS mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Gria4 |
glutamate ionotropic receptor AMPA type subunit 4 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIA4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 8:1,562,118...2,035,035
Ensembl chr 8:1,562,119...2,034,979
|
|
G |
Grik1 |
glutamate ionotropic receptor kainate type subunit 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of GRIK1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr11:27,169,739...27,571,131
Ensembl chr11:27,169,740...27,570,645
|
|
G |
Grik2 |
glutamate ionotropic receptor kainate type subunit 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIK2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of GRIN1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of GRIN2B mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Grip1 |
glutamate receptor interacting protein 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of GRIP1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:54,934,856...55,592,274
Ensembl chr 7:54,934,250...55,592,273
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression |
EXP |
prochloraz results in increased expression of GSR mRNA |
CTD |
PMID:25182419 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of GSTA5 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression |
EXP |
prochloraz results in increased expression of HERPUD1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hes6 |
hes family bHLH transcription factor 6 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of HES6 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 9:92,001,849...92,003,562
Ensembl chr 9:92,001,841...92,003,559
|
|
G |
Hsd17b10 |
hydroxysteroid (17-beta) dehydrogenase 10 |
decreases expression |
EXP |
prochloraz results in decreased expression of HSD17B10 protein |
CTD |
PMID:16375936 |
|
NCBI chr X:21,089,142...21,091,603
Ensembl chr X:21,089,122...21,109,488
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
increases expression |
EXP |
prochloraz results in increased expression of HSD17B2 mRNA |
CTD |
PMID:25182419 |
|
NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
decreases activity decreases expression |
ISO |
prochloraz results in decreased activity of HSD3B2 protein prochloraz results in decreased expression of HSD3B2 mRNA |
CTD |
PMID:19733639 |
|
NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Hspb8 |
heat shock protein family B (small) member 8 |
increases expression multiple interactions |
EXP |
prochloraz results in increased expression of HSPB8 mRNA [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of HSPB8 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases expression |
EXP |
prochloraz results in decreased expression of IGF1 mRNA |
CTD |
PMID:16375936 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf2r |
insulin-like growth factor 2 receptor |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of IGF2R mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:47,979,109...48,067,501
Ensembl chr 1:47,979,109...48,067,501
|
|
G |
Il1rapl1 |
interleukin 1 receptor accessory protein-like 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of IL1RAPL1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr X:51,371,969...52,876,726
Ensembl chr X:51,378,215...52,876,772
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
multiple interactions |
ISO |
prochloraz inhibits the reaction [Dihydrotestosterone results in increased secretion of KLK3 protein] |
CTD |
PMID:25324206 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
prochloraz results in decreased expression of LEP mRNA |
CTD |
PMID:30879083 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lhb |
luteinizing hormone subunit beta |
increases expression |
EXP |
prochloraz results in increased expression of LHB protein |
CTD |
PMID:12377983 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lrrc7 |
leucine rich repeat containing 7 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of LRRC7 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:247,146,616...247,634,945
Ensembl chr 2:247,147,752...247,634,547
|
|
G |
Ly6d |
lymphocyte antigen 6 family member D |
increases expression |
EXP |
prochloraz results in increased expression of LY6D mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 7:106,643,225...106,644,733
Ensembl chr 7:106,643,232...106,644,733
|
|
G |
Magi2 |
membrane associated guanylate kinase, WW and PDZ domain containing 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of MAGI2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 4:14,386,389...15,870,036
Ensembl chr 4:14,386,399...15,870,240
|
|
G |
Manba |
mannosidase beta |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MANBA mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 2:223,910,432...224,002,988
Ensembl chr 2:223,910,432...224,002,983
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
prochloraz inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:31152826 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
prochloraz inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:31152826 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mdga2 |
MAM domain containing glycosylphosphatidylinositol anchor 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of MDGA2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 6:84,746,422...85,608,640
Ensembl chr 6:84,761,941...85,608,126
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MDM2 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mgst2 |
microsomal glutathione S-transferase 2 |
increases expression |
EXP |
prochloraz results in increased expression of MGST2 mRNA |
CTD |
PMID:25182419 |
|
NCBI chr 2:135,679,524...135,715,828
Ensembl chr 2:135,693,557...135,715,828
|
|
G |
Mlh1 |
mutL homolog 1 |
increases expression |
EXP |
prochloraz results in increased expression of MLH1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617
|
|
G |
Mlx |
MAX dimerization protein MLX |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MLX mRNA |
CTD |
PMID:29038839 |
|
NCBI chr10:86,019,216...86,024,326
Ensembl chr10:86,019,588...86,032,350
|
|
G |
Mrps18b |
mitochondrial ribosomal protein S18B |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MRPS18B mRNA |
CTD |
PMID:29038839 |
|
NCBI chr20:2,838,174...2,844,260
Ensembl chr20:2,838,030...2,844,260
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
increases expression multiple interactions |
EXP |
prochloraz results in increased expression of MSMO1 mRNA [cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of MSMO1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
|
|
G |
Nf1 |
neurofibromin 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NF1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658
|
|
G |
Nlgn1 |
neuroligin 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NLGN1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:108,256,236...109,181,530
Ensembl chr 2:108,257,824...109,002,464
|
|
G |
Notch2 |
notch receptor 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of NOTCH2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088
|
|
G |
Notch3 |
notch receptor 3 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of NOTCH3 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:11,132,984...11,184,025
Ensembl chr 7:11,133,706...11,184,025
|
|
G |
Notch4 |
notch receptor 4 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NOTCH4 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr20:4,160,362...4,184,466
Ensembl chr20:4,160,445...4,184,465
|
|
G |
Nploc4 |
NPL4 homolog, ubiquitin recognition factor |
multiple interactions increases expression |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of NPLOC4 mRNA prochloraz results in increased expression of NPLOC4 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr10:105,654,395...105,709,958
Ensembl chr10:105,654,812...105,709,913
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of NQO1 mRNA |
CTD |
PMID:29038839 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases activity |
ISO |
[NR1I2 protein co-treated with NR1I3 protein co-treated with prochloraz] results in increased expression of CYP1A1 mRNA; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [prochloraz results in increased expression of CYP2B10 protein]; prochloraz binds to and results in increased activity of NR1I2 protein prochloraz results in increased activity of NR1I2 protein |
CTD |
PMID:16565514 PMID:21115097 PMID:28058446 PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
[NR1I2 protein co-treated with NR1I3 protein co-treated with prochloraz] results in increased expression of CYP1A1 mRNA; [NR1I2 protein co-treated with NR1I3 protein] affects the reaction [prochloraz results in increased expression of CYP2B10 protein] |
CTD |
PMID:28058446 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nrcam |
neuronal cell adhesion molecule |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of NRCAM mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 6:61,402,813...61,698,536
Ensembl chr 6:61,329,863...61,702,992
|
|
G |
Nrg1 |
neuregulin 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NRG1 mRNA; [Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of NRG1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Nrxn1 |
neurexin 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of NRXN1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 6:3,177,788...4,323,848
Ensembl chr 6:3,177,897...4,322,710
|
|
G |
Nrxn2 |
neurexin 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NRXN2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:203,726,420...203,842,301
Ensembl chr 1:203,735,753...203,842,297
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of NTRK2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions decreases expression |
EXP |
prochloraz inhibits the reaction [Testosterone Propionate results in increased expression of ODC1 mRNA] prochloraz results in decreased expression of ODC1 mRNA |
CTD |
PMID:12377983 PMID:15519604 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Pdyn |
prodynorphin |
increases expression |
EXP |
prochloraz results in increased expression of PDYN mRNA |
CTD |
PMID:29038839 |
|
NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of PGR mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of POR mRNA |
CTD |
PMID:29038839 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression |
ISO |
prochloraz results in increased expression of PPARA mRNA |
CTD |
PMID:30879083 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression multiple interactions |
ISO |
prochloraz results in decreased expression of PPARG mRNA prochloraz binds to and results in increased activity of PPARG protein |
CTD |
PMID:30879083 PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions increases expression |
EXP |
[cyproconazole co-treated with epoxiconazole co-treated with prochloraz] results in increased expression of PPARGC1A mRNA prochloraz results in increased expression of PPARGC1A mRNA |
CTD |
PMID:29038839 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of PRKN mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases activity |
ISO |
prochloraz results in increased activity of RARA protein |
CTD |
PMID:20143881 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Reln |
reelin |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in increased expression of RELN mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211
|
|
G |
Robo1 |
roundabout guidance receptor 1 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ROBO1 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr11:10,580,863...11,621,675
Ensembl chr11:10,580,908...11,620,203
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of RXRA mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Shank2 |
SH3 and multiple ankyrin repeat domains 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SHANK2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 1:199,146,210...199,590,962
Ensembl chr 1:199,169,429...199,589,394
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SLC1A2 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc1a6 |
solute carrier family 1 member 6 |
multiple interactions |
EXP |
[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SLC1A6 mRNA |
CTD |
PMID:25607892 |
|
NCBI chr 7:10,841,836...10,870,424
Ensembl chr 7:10,841,837...10,870,449
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
increases expression |
ISO |
prochloraz results in increased expression of SLC22A1 mRNA |
CTD |
| |